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SUMMARY 
Background: Cardiovascular diseases (CVD) are among the main causes of death 
worldwide. An unhealthy lifestyle, sleep-related breathing disorders and inflammation are all 
significantly and independently associated with an increased risk of cardiovascular events.  
The autonomic nervous system (ANS) is an important player within the cardiovascular 
system. Over the last years, heart rate variability (HRV) has become a validated measure of 
the autonomic function and was found to be associated with several cardiovascular risk 
factors, disease outcomes and mortality. To date, several aspects related to HRV among 
young adults remain unclear.  
Based on those gaps of knowledge, the general aim of this PhD thesis was to assess the 
relationships of HRV with lifestyle, sleep-related breathing disorders and inflammatory 
biomarkers among young and healthy adults from the general population. The specific aims 
were 1) to evaluate the prevalence of a healthy lifestyle and assess its relationship with HRV, 
2) to assess the prevalence of sleep-related breathing disorders and investigate its 
association with HRV and 3) to assess the interrelationships between HRV and blood 
markers of inflammation.  
Methods: This PhD thesis is based on data from the Genetic and Phenotypic Determinants 
of Blood Pressure and other Cardiovascular Risk Factors (GAPP) study, a prospective 
population based cohort study. Overall, 2170 inhabitants of the Principality of Liechtenstein, 
aged between 25-41 years, without established CVD and a BMI ≤35kg/m2 were included in 
this study. Study participants obtained a 24-hour (h) Holter electrocardiogram (ECG), and 
careful post-processing was applied. Time- and frequency domain HRV variables and 
ambulatory heart rate (HR) were exported. The standard deviation of all normal RR intervals 
(SDNN) was pre-specified as the main HRV variable for all analyses. Personal, medical, 
lifestyle and nutritional information were assessed using standardized questionnaires. A 
fasting venous blood sample was taken to determine biomarkers. For assessment of sleep-
related breathing disorders, a nocturnal pulse oximetry with additional nasal airflow recording 
was performed. Resting HR was recorded using a 10-second resting ECG. Multivariable 
linear regression models were constructed using HRV related parameters as the outcome 
variables.  
Results: Overall, 2170 participants (47% male) with a median age of 37 years were 
included. We found that only 11% of our population adopted a healthy lifestyle defined as a 
lifestyle-score of 6 or 7, whereas 5% had a very unhealthy lifestyle defined as a score of 0 or 
1. In general, women had a higher lifestyle-score compared to men. Having a healthy 
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lifestyle was significantly associated with SDNN, with a β-coefficient (95% confidence interval 
(CI)) of 0.14 (0.11; 0.17), p=0.0001 per one point increase in the lifestyle-score. This result 
was attenuated but remained significant after additional adjustment for either resting or 
ambulatory HR. In the second analysis we found that 9.6% of the population had an apnea-
hypopnea index (AHI) ≥5, which is one important component for the diagnosis of an 
obstructive sleep apnea syndrome. After comprehensive multivariable adjustment, SDNN 
was inversely associated with categories of AHI and oxygen desaturation index (ODI). These 
relationships were strongly weakened after the additional adjustment for resting and 24-h HR 
and most of these relationships lost significance. Resting and ambulatory HR by itself were 
positively associated with increasing levels of AHI and ODI categories. However, only the 
relationships with ambulatory HR remained significant after the adjustment for HRV. In the 
final analysis, we found a close and independent link between HRV and inflammatory 
biomarkers. Inverse associations of SDNN with all available inflammatory biomarkers were 
found, with β-coefficients (95%CI) of -0.11 (-0.16;-0.07), p<0.0001 for high-sensitivity C-
reactive protein, -0.13 (-0.17;-0.09), p<0.0001 for total leukocyte count, -0.12 (-0.16;-0.08), 
p<0.0001 for neutrophils, -0.04 (-0.09;0.00), p=0.05 for lymphocytes and -0.08 (-0.09;-0.02), 
p=0.005 for monocytes. These associations were strongly attenuated after additional 
adjustment for ambulatory HR and partly lost significance. Ambulatory HR by itself was 
positively associated with all inflammatory biomarkers, except lymphocytes.  
Conclusion: In this young and healthy population, HRV was significantly related to a 
comprehensive healthy lifestyle, sleep-related breathing disorders and inflammatory 
biomarkers, suggesting an interrelationship between the ANS and these entities. However, 
most of the information seems to be contained in HR, and the incremental information of 
HRV parameters was modest in most analyses. These data may allow some insights in the 
pathophysiology of CVD occurrence. Finally, the adoption of a healthy lifestyle was rather 
low in this population, underscoring the importance of healthy lifestyle promotion in the 
society.  
Outlook: More data are needed on the role of the autonomic function in the development of 
CVD outcomes and on the independent role of HRV in the prediction of cardiovascular risk 
factor progression or outcome occurrence.  
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ZUSAMMENFASSUNG 
Hintergrund: Kardiovaskuläre Erkrankungen gehören weltweit zu den häufigsten Ursachen 
für Morbidität und Mortalität. Ein ungesunder Lebensstil, schlafassoziierte Atemstörungen 
und Entzündung sind unabhängig mit einem erhöhten Risiko für kardiovaskuläre Ereignisse 
assoziiert.  
Das autonome Nervensystem (ANS) spielt eine wichtige Rolle in verschiedenen Prozessen 
des kardiovaskulären Systems. Die Herzfrequenzvariabilität (HRV) gilt als valides Mass der 
autonomen Funktion und ist mit verschiedenen kardiovaskulären Risikofaktoren und 
Mortalität assoziiert. Jedoch sind gerade in einer jungen Population noch einige Aspekte der 
HRV unklar.  
Basierend auf diesen Wissenslücken, war das generelle Ziel dieser Arbeit herauszufinden, 
ob es in einer jungen und gesunden Population einen Zusammenhang zwischen der HRV 
und dem Lebensstil, schlafassoziierten Atemstörungen und Entzündungswerten gibt. Die 
spezifischen Ziele waren 1) die Prävalenz eines gesunden Lebensstils zu berechnen und 
den Zusammenhang zwischen der HRV und dem Lebensstil zu quantifizieren, 2) die 
Prävalenz von schlafassoziierten Atemstörungen in einer gesunden Population zu berechnen 
und die Beziehung mit der HRV herzustellen und 3) die Wechselwirkung zwischen der HRV 
und den verschiedenen Entzündungsmarkern herzustellen. 
Methoden: Diese PhD Arbeit basiert auf den Daten der Genetic and Phenotypic 
Determinants of Blood Pressure and other Cardiovascular Risk Factors (GAPP) Studie, einer 
populations-basierten Kohortenstudie. Insgesamt konten 2170 im Fürstentum Liechtenstein 
wohnhafte Personen im Alter zwischen 25 und 41 Jahren, ohne kardiovaskuläre 
Vorerkrankungen und einem body mass index (BMI) ≤35kg/m2 vor Ort in die Studie 
eingeschlossen werden. Bei allen Studienteilnehmern wurde ein 24-Stunden 
Elektrokardiogramm (EKG) aufgezeichnet und im Anschluss manuell nachbearbeitet. Die 
zeit- und frequenzbasierten HRV Variablen, sowie die Herzfrequenz (HR) wurden exportiert. 
Die Standardabweichung aller RR Intervalle (SDNN) haben wir als primäre HRV Variable 
vorgängig bestimmt. Informationen zur Person, der medizinischen Vorgeschichte und den 
Lebensstilfaktoren wurden mittels standardisierter Fragebögen erhoben. Zur Bestimmung 
wichtiger Biomarker erfolgte eine Nüchtern-Blutentnahme. Um schlafassoziierte 
Atemstörungen detektieren zu können, wurde eine nächtliche Pulsoxymetrie mit zusätzlicher 
Atemflussmessung durchgeführt. Die Ruhe HR wurde mit einem 12-Kanal Ruhe-EKG 
bestimmt. Mittels multivariaten Regressionsmodellen wurden die Zusammenhänge zwischen 
der HRV als abhängige Variable und den verschiedenen Prädiktoren berechnet.  
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Resultate: Insgesamt wurden 2170 Studienprobanden (47% männlich) mit einem mittleren 
Alter von 37 Jahren in die Studie eingeschlossen. Der Lebensstil-Score ergab bei 11% der 
Studienpopulation einen Wert von 6 oder 7 (sehr gesund) wohingegen 5% einen sehr 
ungesunden Lebensstil mit einem Score von 0 oder 1 hatten. Im Vergleich zu Männern 
zeigte sich bei Frauen ein höherer Lebensstil-Score. Ein gesunder Lebensstil war positiv 
assoziiert mit der HRV, mit einem β-Koeffizienten (95% Konfidenzinterval (CI)) von 0.14 
(0.11; 0.17), p=0.0001 pro Punktanstieg im Lebensstil-Score. Die zusätzliche Adjustierung 
für die Ruhe- und 24-h HR hat den Zusammenhang abgeschwächt, jedoch blieb der 
Zusammenhang signifikant. In einer zweiten Analyse zeigte sich eine Prävalenz von 9.6% für 
schlafassoziierte Atemstörungen (apnea-hypopnea index (AHI) ≥5). Auch nach einer 
multivariaten Korrektur gab es signifikante, inverse Zusammenhänge zwischen der SDNN 
und dem AHI und ODI (oxygen desaturation index), welche jedoch nach zusätzlicher 
Adjustierung durch die Ruhe- und 24-h HR nur noch teilweise signifikant waren. In der dritten 
Analyse haben wir signifikante und unabhängige Zusammenhänge zwischen der HRV und 
allen verfügbaren Entzündungsparametern gefunden. Die SDNN war invers assoziiert mit 
allen verfügbaren Entzündungsmarkern mit einem β-Koeffizienten (95%CI) von -0.11 (-0.16;-
0.07), p<0.0001 für hoch-sensitives C-reaktives Protein, -0.13 (-0.17;-0.09), p<0.0001 für 
Leukozyten, -0.12 (-0.16;-0.08), p<0.0001 für neutrophile Granulozyten, -0.04 (-0.09;0.00), 
p=0.05 für Lymphozyten und -0.08 (-0.09;-0.02), p=0.005 für Monozyten. Die zusätzliche 
Korrektur für HR, welche auch unabhängig mit den Entzündungsmarkern assoziiert war, hat 
die Wechselbeziehung zwischen der HRV und den Entzündungsmarkern deutlich 
abgeschwächt.  
Schlussfolgerungen: In dieser jungen und gesunden Population war die HRV signifikant 
assoziiert mit einem gesunden Lebensstil, schlafassoziierten Atemstörungen und 
Entzündungswerten. Deshalb kann von einer Wechselwirkung zwischen der autonomen 
Funktion und den drei Entitäten ausgegangen werden. Jedoch scheint die HR den Grossteil 
der Information zu enthalten und die zusätzliche Information der HRV zeigte in den meisten 
Analysen nur moderate Auswirkungen. Diese Resultate können Einblicke in die 
Pathophysiologie der Entstehung kardiovaskulärer Erkrankungen ermöglichen. Ausserdem 
war die Prävalenz eines gesunden Lebensstils eher gering, was die Wichtigkeit für 
strukturierte Präventionsprogramme aufzeigt.  
Ausblick: Weitere Daten sind notwendig um einerseits die Rolle der autonomen Funktion in 
der Entwicklung von kardiovaskulären Erkrankungen zu verstehen und andererseits die Rolle 
der HRV für die Prädiktion von kardiovaskulären Events besser untersuchen zu können.  
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1.BACKGROUND 
1.1 Cardiovascular disease – public health impact and risk factors 
Cardiovascular diseases (CVD) are among the main causes of death worldwide, causing 
approximately 48% of all deaths due to non-communicable diseases.1-4 The global burden of 
CVD is expected to further increase in the upcoming decades, which will have an additional 
impact on the health care systems.3 Cerebrovascular and ischemic heart diseases have the 
highest impact on CVD mortality among men and women.1 Age and other cardiovascular risk 
factors are additively increasing lifetime-risk for death from CVD (Figure 1).5 Consequently, a 
reduction in CVD related morbidity and mortality largely depends on avoidance and optimal 
management of its modifiable risk factors. Accordingly, ideal cardiovascular health metrics 
are strongly recommended by professional societies.6,7 
 
 
 
 
 
 
 
 
 
1.1.1 Lifestyle – and cardiovascular risk factors 
A healthy lifestyle represents a key component to improve cardiovascular risk factors, and to 
reduce the development of CVD. The Global Burden of Disease Study in 2013 showed that 
the population attributable risk for death from CVD of known cardiovascular risk factors was 
88.5%, suggesting that avoiding these factors in the population would greatly reduce the 
occurrence of CVD.4 Other studies also highlighted, that the number of ideal lifestyle factors 
and cardiovascular health metrics is strongly associated with a lower rate of CVD and all-
cause mortality in general population,8,9 which further highlights the importance of adopting a 
healthy lifestyle.  
Figure 1 Lifetime risk of death from cardiovascular disease among men at 55 
years of age, according to the burden of risk factors (Berry et al., N Engl J Med, 
2012) 
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Previous studies found an association of diet, physical activity, body mass index (BMI) and 
smoking status with the risk for cardiovascular events.10-12 Compared to women with a 
normal BMI, obese women had a 57% increased risk for cardiovascular events. Additionally, 
being physically active resulted in a 41% reduced risk for such events.11 Among elderly 
adults, higher walking pace and walking distance were associated with a 40 to 50% risk 
reduction for CVD.13 Based on data of the Nurses’ Health Study, Chomistek et al. have 
indicated that having a normal BMI and being physically active were the most important 
components to avoid the development of coronary heart disease.12 According to these 
results, accomplishing either one of those components may prevent around one fifth of all 
newly diagnosed cases of coronary heart disease.12 Adopting an unhealthy lifestyle is 
associated with most major cardiovascular risk factors, including hypertension, Type 2 
Diabetes mellitus (T2DM) or dyslipidemia.12 Taken together, having ideal lifestyle factors is a 
key component in CVD prevention.  
1.1.2 Sleep-related breathing disorders 
Sleep-related breathing disorders include multiple entities,14 while the obstructive sleep 
apnea (OSA) syndrome is the most prevalent in the general population.15 OSA is 
characterized by repetitive partial or complete obstructions during sleep caused by collapsing 
airways with following arousals.16 Sleep-related breathing disorders are highly prevalent and 
remain often undiagnosed.17 20 years ago, the estimated prevalence of sleep-related 
breathing disorders among women and men was 9 and 24%, respectively.17 In a recently 
published population-based study of 2100 individuals with performed polysomnography, 
Heinzer et al. found a prevalence of moderate to severe sleep-related breathing disorders of 
23% in women and 50% in men.15 OSA is independently associated with an increased risk of 
hypertension,18-20 coronary artery disease,21 cerebrovascular events22 and sudden cardiac 
death.23 Studies showed that adequate treatment of overt OSA is associated with a lower risk 
of cardiovascular outcomes.21,24 Obesity represents the main risk factor for the development 
of an OSA. A study including middle-aged adults also highlighted that age and male sex are 
independent predictors for incident sleep-related breathing disorders.25 BMI and sex seem to 
become less important predictors with increasing age.25 In addition to those predictors, 
others found associations of OSA with T2DM, cholesterol, metabolic syndrome and 
depression, even after the adjustment for BMI, waist-to-hip ratio (WHR) or neck 
circumference.15,26 Since overweight and obesity are epidemic, an increasing prevalence of 
sleep-related breathing disorders in the general population is expected in the future.  
The main measures of sleep-related breathing disorders are the apnea-hypopnea index 
(AHI) and the oxygen desaturation index (ODI). AHI is defined as the average number of 
apnea and hypopnea episodes per hour of sleep. An apnea/hypopnea event is characterized 
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as a complete cessation or a fading reduction in breathing over at least 10 seconds14 The 
ODI is corresponding to the number of oxygen desaturations of ≥4% per hour of recording. 
According to official guidelines, a diagnosis of an OSA consists of having an AHI ≥5 and 
additional symptoms, such as excessive daytime sleepiness, recurrent awakenings form 
sleep, snoring or markedly impaired concentration during daytime.14 As a definition of sleep-
related breathing disorders, an AHI ≥5 is most commonly used in literature.15  
1.1.3 Inflammation 
Inflammation consists of different biological reactions protecting the body against pathogens. 
Over recent years, inflammation has shown to be strongly involved in the pathogenesis of 
atherosclerosis.27 Lowering inflammation could therefore be a potential therapeutic goal, 
which is currently topic of intense research activities.27 
Several inflammatory biomarkers are highly related to the development of CVD.28 Especially, 
the relationship of high-sensitivity C-reactive protein (hs-CRP) with cardiovascular outcomes 
is well studied, showing a positive association between hs-CRP levels and death from 
CVD.29-31 A meta-analysis including 31 studies showed a linear relationship between hs-CRP 
and the risk for coronary heart disease, ischemic stroke and vascular deaths.32 Additionally, 
hs-CRP and fibrinogen were strongly associated with the development of atrial fibrillation.33,34 
Finally, Interleukin-6 (IL-6), an important cytokine with a broad range of immune effects, is 
associated with the risk of myocardial infarction.35  
Inflammatory biomarkers are strongly influenced by different lifestyle factors. BMI was 
positively associated with inflammation, assuming a low-grade systemic inflammation in 
obese individuals. Moreover a high WHR, indicative for a high amount of visceral body fat, 
was independently associated with inflammation among men and women.36 Adipose tissue is 
releasing cytokines and may therefore explain the relationship between obesity and systemic 
inflammation. Another study showed a negative dose-response relationship between 
physical activity and inflammation that was independent of BMI.37 This anti-inflammatory 
effect of regular physical activity was confirmed by other studies and is summarized in a 
systematic review.38 Past and current smoking was positively associated with hs-CRP, 
leukocytes (LC), IL-6 and fibrinogen.39,40 
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1.2 Heart rate variability and the autonomic nervous system 
The autonomic nervous system (ANS) plays an important role in the regulation and function 
of the cardiovascular system and helps to adapt the cardiovascular system to environmental 
demands.41 The ANS consists of two major branches, the sympathetic and parasympathetic 
nervous system, which should be well-balanced. With regard to heart rate (HR) and rhythm, 
the sinus node is directly regulated via efferent sympathetic and parasympathetic nerve 
activities. The sympathetic nervous system has a positive chrono-, dromo- and inotrope 
effect, which is corresponding to an increase in HR, a faster conduction speed in the AV-
node and a higher myocardial contractibility. The parasympathetic system has the inverse 
effect. Chronic sympathetic overactivity is associated with the development of CVD.42 Thus a 
well-balanced ANS is important to prevent the development of CVD events.  
The heart rate variability (HRV) represents the beat-to-beat variation of the HR, a component 
strongly regulated by autonomic inputs to the sinus node (Figure 2). Those variations can be 
quantified using HRV analysis, which has become a validated measure of the autonomic 
modulation.43,44 HRV can be easily assessed using a short-term ECG, or alternatively 
measured using a 24-hour (h) ECG, while individuals perform their daily activities, and which 
represents the current gold standard. Based on all normal RR intervals, HRV can be 
analyzed by either time- or frequency domain. Most important HRV variables are presented 
in the Table below. 
 
  
Figure 2 Variance in RR intervals 
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Table Time- and frequency domain HRV indices and their significance 
Referring to European to the Task Force of the European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology. SDNN = standard deviation of normal RR intervals; HF = high frequency; LF = low frequency; VLF = very low 
frequency; TP = total power 
 
Time domain heart rate variability 
All normal RR intervals are measured over the recording time and different measures can be 
derived based on those intervals. The standard deviation of all normal RR intervals (SDNN) 
is one of the most commonly used HRV variables for research proposes and, in contrast to 
frequency-domain variables, relatively easy to understand. SDNN is depending on the length 
of the ECG recording, hence it is important to be attentive regarding the comparability of 
absolute HRV values with other studies. Therefore it is an advantage to use standardized 24-
h ECG monitorings.43  
 
Frequency domain heart rate variability 
Frequency domain HRV indices, measured in ms2, contain information about the amount of 
variance in HR.45,46 Differences in HR (RR intervals) are underlying certain oscillatory 
patterns. According to the frequency of these oscillations (Figure 3, left), they are grouped in 
different frequency bands, such as high or low frequency. Mainly Fast Fourier Transformation 
is used to convert these signals to a spectral analysis, showing the power of all individual 
frequency bands (Figure 3, right). The high frequency (HF) band is corresponding to a 
frequency of 0.15-0.40 Hertz (Hz) (i.e. 2.5 - 7 seconds), which is mainly modulated by 
parasympathetic activity. In contrast the low frequency (LF) band is defined as a frequency of 
Variable Frequency band 
(Hertz) 
Description 
SDNN - 
Standard deviation of all normal RR intervals, reflects 
total variability, including circadian differences 
HF 0.15-0.40 
High frequency component, mainly controlled by 
parasympathetic activity 
Normalized HF - HF/(TP-VLF); HF independent of total power 
LF 0.04-0.15 
Low frequency component, controlled by sympathetic and 
parasympathetic activity 
Normalized LF - LF/(TP-VLF); LF independent of total power 
VLF 0.0033-0.04 
Very low frequency component, controlled by sympathetic 
and parasympathetic activity 
TP ≤0.40 Variance of all RR intervals 
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0.04-0.15 Hz (i.e. 7 - 25 seconds) and modulated by both, sympathetic and parasympathetic 
activity. Total power (TP) is corresponding to the total variance of all RR intervals.43 LF and 
HF may be normalized in order to have values independent of TP.  
 
 
1.2.1 Heart rate variability and cardiovascular outcomes 
Several studies found a relationship between short- and long-term HRV and adverse 
cardiovascular outcomes. Lower SDNN was significantly associated with an increased risk 
for adverse cardiac events in the general population.47-50 Among patients with a history of 
myocardial infarction, having a SDNN <70ms was associated with an increased risk for future 
cardiovascular events.51,52 Data from the ARIC (Atherosclerosis Risk in Communities) study 
indicated an increased risk for incident myocardial infarction and coronary heart disease 
among diabetic patients.53 Moreover, HRV was associated with a higher incidence of heart 
failure.54 However, even though there is a growing literature about HRV and cardiovascular 
outcomes, the precise underlying mechanisms of the relationship between the autonomic 
function and those outcomes are not fully understood. In addition, it remains unclear, to what 
extent HRV measures contain information independent of HR, as highlighted in a recent 
publication.55  
1.2.2 Heart rate variability and healthy lifestyle 
HRV linearly decreases with age.56,57 Recent studies found associations of HRV with several 
cardiovascular risk and lifestyle factors.58 Specifically, HRV was associated with smoking 
cigarettes,59 physical activity,60-62 T2DM,63,64 hypertension65,66 and BMI.60 Using data of the 
ARIC study, Schroeder et al. found a 24% increased risk of hypertension among participants 
in the lowest SDNN quartile compared to participants in the highest SDNN quartile.66 In the 
same cohort, patients with an impaired fasting glucose or a manifest T2DM had a 
significantly reduced HRV compared to participants with normal glucose levels.63 These 
Figure 3 Periodic oscillations based on differences of the RR intervals (left) and spectral analysis of RR 
interval variability (right) (Stein et al., Am Heart J, 1994 and Task Force of the European Society of 
Cardiology, Circulation, 1996) 
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results were adjusted in multivariable models and therefore independent of other known 
confounders. According to data of the SAPALDIA (Swiss Study on Air Pollution and Lung 
Disease in Adults) study, current smokers had a 4.5% lower SDNN compared to never 
smokers. Moreover, per 1-point increase in BMI, SDNN is lowered by 0.7%. In contrast, 
individuals performing regular physical activity had a 2% higher SDNN compared to 
physically inactive individuals.58 This is in line with another study, showing a positive 
association between the time spent for physical activity and SDNN.61  
Adopting a healthy lifestyle is highly promoted by associations and governments. In order to 
better target future campaigns, a better knowledge of the prevalence of healthy lifestyle 
adoption in a contemporary western European population is needed. Moreover, while some 
individual parameters have been related to autonomic function, it is currently unknown 
whether these cardiovascular health metrics in combination have an incremental effect on 
autonomic function. Finally, most prior studies have not taken into account the effect of HR, 
and it is therefore unknown whether HRV carries any incremental information beyond HR 
alone in this context. 
1.2.3 Heart rate variability and sleep-related breathing disorders 
Clinical studies assessing the relationship between sleep-related breathing disorders and 
HRV in general population are scarce. In a very small study, OSA patients had a significantly 
worse HRV profile and a higher HR compared to healthy controls.67 Moreover, patients with 
moderate to severe OSA had significantly higher normalized LF and lower normalized HF 
compared to controls.68,69 Another small study presented a negative association between 
normalized HF and the number of respiratory disturbances.70  
Taken together, only few studies showed associations of HRV with overt OSA and 
population-based studies regarding this topic are rare. The relationship of HRV with 
preliminary stages of sleep-related breathing disorders is uncertain. Moreover, the 
prevalence of sleep-related breathing disorders in a young and healthy population is 
unknown. Again, the incremental information of HRV beyond resting HR is also unknown in 
this context.  
1.2.4 Heart rate variability and inflammation 
Up to now, some studies have assessed the relationship of mainly hs-CRP with HRV or HR 
mainly in elderly populations. In a previous study, hs-CRP was inversely associated with 
SDNN. Moreover, SDNN was a significant predictor for having high CRP levels, defined as 
the upper third of this middle-aged population.71 These results were confirmed by another 
study, showing inverse associations of hs-CRP with LF, TP and SDNN.72 The association 
between HRV and hs-CRP was not only found among healthy populations but also among 
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patients with coronary heart disease.73 Lampert et al. found a significant correlation between 
HRV and IL-6, however this relationship did not persist using multivariable regression 
models.74 Finally, there was a significant inverse correlation between time-domain HRV 
variables and total LC count.75  
Inflammation is complex and consists of different inflammatory pathways and biomarkers. 
Regarding the relationship with HRV, information on inflammatory biomarkers other than hs-
CRP is scarce. Inflammation is highly related to other cardiovascular risk factors. Therefore, 
an appropriate adjustment in well-characterized cohorts is needed. As well, the association 
of HRV and inflammatory biomarkers should be adjusted for HR to evaluate potential 
incremental information of HRV over HR. 
1.2.5 Heart rate 
Previous studies found strong associations of resting and ambulatory HR with an increased 
risk for cardiovascular outcomes.76,77 Moreover, HR was found to be associated with some 
individual cardiovascular health metrics or lifestyle factors, individual inflammatory 
biomarkers and OSA.68,78-80 Monfredi et al. have recently presented a tight inverse, but 
nonlinear link between HR and time-domain HRV (Figure 4).55 Based on data of the 
Framingham study, Tsuji et al. showed years ago similar inverse relationships with 
frequency-domain variables, such as LF and HF.81 Based on this tight link, it is suggested to 
take HR into account when investigating associations with HRV, to assess relationships 
independent of HR. To date, this additional adjustment for HR was only done in very few 
studies and should therefore be better elaborated. 
  Figure 4 Relationship between SDNN and heart rate (Monfredi 
et al., Circulation, 2015) 
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2.AIMS AND OBJECTIVES 
Based on the previously elucidated gaps in knowledge, the general aim of this study was to 
assess the relationship of HRV with lifestyle and lifestyle-related factors in young and healthy 
adults from the general population. 
2.1 Healthy lifestyle and heart rate variability 
The aim of this study was to assess the relationship of HRV with a validated lifestyle-score 
among young and healthy adults from the general population.  
Objectives 
1. To build a validated lifestyle-score based on seven lifestyle factors and health 
metrics.  
2. To investigate the prevalence of a healthy lifestyle in the general population. 
3. To assess the relationship of HR and HRV related parameters with a validated 
lifestyle-score. 
4. To assess the incremental information of HRV with a validated lifestyle-score after 
adjustment for resting and ambulatory HR. 
5. To investigate the relationship of every individual lifestyle-score component with the 
main HRV variable (i.e. SDNN). 
Specific research questions 
1. What is the prevalence of a healthy lifestyle among young men and women from a 
western European general population sample? 
2. Is there a relationship between different HRV variables and a healthy lifestyle? 
3. Is there a relationship between different HRV variables and a healthy lifestyle that is 
independent of resting or ambulatory HR? 
4. Which components of the lifestyle-score are independently associated with HRV? 
The results are presented in the manuscript Healthy lifestyle and heart rate variability in 
young adults, which has been published in the European Journal of Preventive Cardiology 
(see manuscript in Chapter 4 on page 17). This study was also presented at the Meeting of 
the European Society of Cardiology in 2015 in the Young Investigator Award Session for 
Population Science.  
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2.2 Heart rate variability and sleep-related breathing disorders 
The aim of this study was to evaluate the association of HRV and sleep-related breathing 
disorders in a young population without known sleep apnea syndrome.  
Objectives 
1. To assess the prevalence of sleep-related breathing disorders in the general 
population without known sleep apnea syndrome. 
2. To assess the relationship of HR and HRV related parameters with sleep-related 
breathing disorders. 
3. To assess the relationship of ambulatory HR with AHI and ODI. 
4. To assess the incremental information of HRV with AHI, ODI and sleep-related 
breathing disorders after the additional adjustment for either resting and ambulatory 
HR. 
Specific research questions 
1. What is the prevalence of sleep-related breathing disorders in young and healthy 
adults from the general population? 
2. Is there an association of different HRV variables with sleep-related breathing 
disorders? 
3. Is resting and ambulatory HR associated with sleep-related breathing disorders? 
4. Is there a relationship between different HRV variables and sleep-related breathing 
disorders that is independent of resting or ambulatory HR? 
The results are presented in the manuscript Heart rate variability and sleep-related 
breathing disorders in the general population, which has been submitted to the 
“American Journal of Cardiology”. This analysis was presented as Poster at the Meeting of 
the American Heart Association (AHA) 2015 in Orlando, USA. Please find this manuscript in 
chapter 5 on page 33. 
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2.3 Heart rate, heart rate variability and inflammatory biomarkers 
The aim of this study was to evaluate the association between the HRV and inflammatory 
biomarkers in a young and healthy population.  
Objectives 
1. To assess the relationships of HR and HRV related variables with a panel of different 
inflammatory biomarkers.  
2. To assess the incremental information of HRV with inflammatory biomarkers after the 
adjustment for ambulatory HR. 
Specific research questions 
1. Is there a relationship of different HRV variables with hs-CRP, LC, neutrophils, 
lymphocytes and monocytes? 
2. Is there a relationship between ambulatory HR and inflammatory biomarkers? 
3. Is there a relationship between different HRV variables and inflammatory biomarkers 
that is independent of HR? 
The results of this analysis are presented in the manuscript Heart rate, heart rate variability 
and inflammatory biomarkers among young and healthy adults, which has been 
submitted to the journal “Annals of Medicine”. Please find the manuscript in chapter 6 on 
page 57.  
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Invitation 
n = 6887 
Participation 
n = 2170 (38%) 
Not reached 
n = 989 (14%) 
Refused 
n = 3605 (62%) 
Exclusion criteria: 
Pregnancy: n = 66 (1%) 
Other: n = 57 (0.8%) 
Eligible Individuals 
contacted 
n = 5775 (84%) 
3.STUDY DESIGN AND METHODS 
3.1 Design and Participants 
This thesis is based on data of the Genetic and Phenotypic Determinants of Blood Pressure 
and other Cardiovascular Risk Factor (GAPP) study, a prospective, population-based cohort 
study. Between 2010 and 2013, all (n=6887) inhabitants of the Principality of Liechtenstein 
aged 25 to 41 years were invited to participate in this study. Based on cooperation with the 
health department in the Principality of Liechtenstein we had the possibility to write to all 
inhabitants in our age range. Of them, 84% were eligible and could be contacted by phone. 
Overall, 2170 individuals agreed to participate and were included in GAPP. Study recruitment 
is presented in Figure 5. The local ethics committee approved the study protocol. A written 
informed consent was obtained from every participant. We have published the detailed study 
methodology previously.82 
 
 
 
 
 
Figure 5 Recruitment of the GAPP-study 
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Inclusion criteria:  
- Inhabitants of the Principality of Liechtenstein  
- Aged between 25 to 41 years  
Exclusion criteria:  
- Any established CVD, such as coronary artery disease, peripheral artery disease, 
congestive heart failure, significant arrhythmia or history of stroke 
- Known OSA 
- Renal disease or renal failure 
- BMI>35 kg/m2  
- Current intake of antidiabetic drugs or insulin 
- Regular intake of steroids, nonsteroidal anti-inflammatory drugs and 
sympathomimetic drugs 
- Current pregnancy 
- Intention to leave the Principality of Liechtenstein on a permanent basis 
 
3.2 Study Procedures 
Study enrollment was managed by trained study nurses in the local study center in Schaan, 
Principality of Liechtenstein. All study related procedures were performed in a highly 
standardized manner.  
3.2.1 24-hour electrocardiogram 
24-h ECG was performed in every participant using a validated three-channel device 
(AR12plus, Schiller AG, Baar, Switzerland). The device was started in the morning at the end 
of the study investigation. If the recording quality was low or the recording duration was 
<80% of the maximal duration (24 hours), participants were asked to repeat the ECG 
recording. Data were imported into a dedicated software (MedilogDARWIN V2, Schiller AG, 
Baar, Switzerland) and systematically edited in order to remove artefacts and redefine 
premature atrial or ventricular beats. Ambulatory HR was calculated automatically over 24 
hours. Time- and frequency domain variables that were used for this study included SDNN, 
TP, LF and HF.  
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3.2.2 Assessment of lifestyle factors and other variables 
Personal, medical, lifestyle and nutritional factors were assessed using standardized 
questionnaires. Age was calculated as the difference between inclusion date and birthday. 
Highest educational level achieved or current educational training was assessed. Smoking 
status was self-reported and categorized into current, former or never smoking. Physical 
activity was defined using the International Physical Activity Questionnaire (IPAQ)83 and 
dietary habits were assessed using the official questionnaire of the Federal Office of Public 
Health (Swiss health survey, 2007). The frequency of alcohol consumption was self-reported 
from a validated questionnaire. Weight and height were measured in a standardized way with 
validated devices (Seca, Hamburg, Germany). Conventional systolic and diastolic blood 
pressure were measured three times in a sitting position after five minutes of rest before and 
with one minute intervals between the measurements using a validated device (Microlife, 
BP3AG1, Taipei, Taiwan). Resting HR was obtained using a 12-channel Resting ECG over 
10 seconds. Bioelectrical impedance analysis was used to assess body composition (BIA 
egofit, Eggstätt, Germany).  
3.2.3 Blood sampling 
Fasting venous blood samples were obtained from every participant by venipuncture and 
immediately processed in an accredited laboratory. High-density lipoprotein cholesterol 
(HDL-C), low-density lipoprotein cholesterol (LDL-C), creatinine and hs-CRP were assayed 
on a Roche Cobas (Roche, Basel, Switzerland) analyzer and glycated hemoglobin A1c 
(HbA1c) was quantified using high performance liquid chromatography (Bio-Rad D-10, Bio-
Rad Laboratories AG, Cressier, Switzerland). White blood cell count, such as leukocytes, 
neutrophils, lymphocytes and monocytes were quantified using a validated method (Sysmex 
XE 5000, Sysmex, Japan).  
3.2.4 Nighttime pulse oximetry and nasal airflow measurement 
Participants obtained a nocturnal pulse oximetry with nasal airflow measurement using a 
validated device (Apnea Link, Resmed, San Diego, USA). Recording was started by the 
participant before falling asleep and was stopped when waking up in the morning. Recording 
had to be at least >180minutes for both pulse oximetry and nasal airflow measurement, 
otherwise the recording was repeated whenever possible. Oxygen saturation was measured 
on the forefinger using a pulse oximetry device and nasal airflow was detected with a nasal 
cannula. AHI and ODI were defined according official guidelines.14 AHI was defined as the 
average number of apnea and hypopnea episodes per hour of sleep. An apnea was defined 
as a nasal airflow reduction of at least 80% during ≥10 seconds. A hypopnea was defined as 
a nasal airflow reduction of ≥30% with a concomitant decrease in oxygen saturation of ≥4%. 
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ODI was defined as the mean number of oxygen desaturations of ≥4% per hour of 
recording.14  
 
3.3 Statistical analysis 
For all analyses, distribution of continuous variables was checked using skewness, kurtosis 
and visual inspection of the histogram. Baseline characteristics were presented as means ± 
standard deviations (SD), medians (interquartile ranges) or numbers (percentages), as 
appropriate. According the distribution of continuous variables, group comparisons were 
done using unpaired t-tests or Wilcoxon rank sum tests. Dichotomous variables were 
compared using Chi-square tests.  
The relationships of HRV with lifestyle, sleep-related breathing disorders and inflammation 
were assessed using HRV variables as the outcome variables. All relationships were 
checked for linearity using categories of the independent variables. P for trend was 
calculated using category-specific medians. To have a better comparability of the estimates, 
HRV variables were transformed to z-scores, calculating (HRV – HRV population mean)/ SD. 
All linear regression models were adjusted for a broad set of potential confounders. Separate 
regression models were constructed with additional adjustment for HR. Analysis-specific 
statistical methods are explained in the manuscripts (chapter 3-6).  
A p-value of <0.05 was pre-specified as level of statistical significance. All statistical analyses 
were performed using the software SAS version 9.4 (SAS Institute Inc, Cary, North Carolina, 
USA).  
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Figure legend 
Figure S1: Relationship between heart rate variability and lifestyle-score 
Data are β coefficients (95% confidence interval) per 1-category increase in the lifestyle-
score. SDNN, High and low frequency were transformed to z-scores. Model 1: adjusted for 
age, sex, educational status, alcohol consumption and family history for cardiovascular 
disease. Model 2: additionally adjusted for resting heart rate. Model 3: additionally adjusted 
for ambulatory heart rate instead of resting heart rate. SDNN = standard deviation of all 
normal RR intervals; ms = millisecond;  
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Table S1 Relationship between variables of the heart rate variability and a modified lifestyle-score 
Values are β coefficient (95% confidence interval). SDNN, High and low frequency were transformed to z-scores. Low-density lipoprotein cholesterol was added 
to the score instead of total cholesterol. Model 1: adjusted for age, sex, educational status, alcohol consumption and family history for cardiovascular disease. 
Model 2: additionally adjusted for resting heart rate. Model 3: additionally adjusted for ambulatory heart rate instead of resting heart rate. SDNN = standard 
deviation of all normal RR intervals; Ms = millisecond; Ref. = reference. 
 
  
N=2079 Score = 0-1 (n=62) 
Score = 2 
(n=198) 
Score = 3 
(n= 382) 
Score = 4 
(n= 585) 
Score = 5 
(n= 571) 
Score = 6-7 
(n= 281) p for trend 
 
SDNN (ms) 
Model 1 -0.40 (-0.65; -0.15) -0.20 (-0.35; -0.05) -0.10 (-0.22; 0.02) 
Ref. 
0.24 (0.13; 0.35) 0.35 (0.21; 0.48) <0.0001 
Model 2 -0.16 (-0.39; 0.06) -0.08 (-0.22; 0.06) -0.03 (-0.14; 0.08) 0.15 (0.05; 0.25) 0.20 (0.08; 0.32) <0.0001 
Model 3 0.07 (-0.14; 0.30) -0.03 (-0.16; 0.10) -0.02 (-0.12; 0.09) 0.16 (0.06; 0.24) 0.16 (0.04; 0.27) 0.001 
 
High Frequency (ms2) 
Model 1 -0.51 (-0.75; -0.26) -0.11 (-0.26; 0.04) -0.12 (-0.24; -0.00) 
Ref. 
0.18 (0.07; 0.29) 0.27 (0.14; 0.41) <0.0001 
Model 2 -0.30 (-0.52; -0.07) 0.003 (-0.13; 0.14) -0.06 (-0.17; 0.05) 0.10 (-0.00; 0.20) 0.15 (0.02; 0.27) 0.0002 
Model 3 0.03 (-0.23; 0.18) 0.06 (-0.06; 0.19) -0.04 (-0.14; 0.06) 0.09 (-0.00; 0.18) 0.08 (-0.04; 0.19) 0.12 
 
Low Frequency (ms2) 
Model 1 -0.58 (-0.81; -0.34) -0.12 (-0.26; 0.03) -0.15 (-0.27; -0.03) 
Ref. 
0.18 (0.07; 0.28) 0.26 (0.13; 0.40) <0.0001 
Model 2 -0.37 (-0.59; -0.16) -0.009 (-0.14; 0.12) -0.09 (-0.20; 0.01) 0.10 (0.002; 0.19) 0.14 (0.02; 0.25) <0.0001 
Model 3 -0.16 (-0.36; 0.05) 0.03 (-0.09; 0.16) -0.08 (-0.18; 0.02) 0.10 (0.01; 0.19) 0.09 (-0.02; 0.21) 0.003 
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Table S2 Subgroup analyses for the relationship between SDNN and the lifestyle-score 
  number β-coefficient (95% CI) p for interaction 
Sex 
Men n=972 0.14 (0.09; 0.19) 
0.35 
Women n=1107 0.13 (0.09; 0.18) 
Age (years) <35 n=882 0.11 (0.05; 0.17) 0.06 
≥ 35 n=1197 0.16 (0.12; 0.20) 
BMI (kg/m2) <25 n=1226 0.14 (0.08; 0.20) 0.26 
≥ 25 n=853 0.08 (0.02; 0.14) 
Smoking  
never n=1141 0.16 (0.11; 0.21) 
0.67 
ever n=938 0.11 (0.06; 0.17) 
Regular physical activity 
(moderate and vigorous) 
< 150 or <75min n=401 0.10 (0.03; 0.17) 
0.60 
≥ 150 or ≥75min n=1678 0.12 (0.08; 0.16) 
Systolic and diastolic Blood 
pressure (mmHg) 
< 120 and 80 without trt n=904 0.12 (0.06; 0.18) 
0.24 
≥ 120 or 80 or trt n=1175 0.15 (0.10; 0.20) 
Cholesterol level (mg/dl) < 200  n=1363 0.15 (0.10; 0.20) 0.86 
≥ 200 n=716 0.13 (0.06; 0.19) 
HbA1c level (%) 
< 5.7 n=1583 0.17 (0.12; 0.21) 
0.96 
≥ 5.7 n=496 0.18 (0.10; 0.25)  
Healthy diet (items) <2  n=1992 0.14 (0.11; 0.18) 0.68 
≥2 n=87 0.18 (0.01; 0.34) 
Education 
high school n=170 0.10 (-0.03; 0.22) 
0.88 college n=1132 0.14 (0.09; 0.18) 
university n=777 0.15 (0.09; 0.20) 
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SDNN was transformed to z-score. Data are β coefficients (95% confidence Interval) adjusted for sex, age, alcohol consumption, educational status, family 
history of cardiovascular disease. SDNN = standard deviation of all normal RR intervals; BMI = body mass index; CI = confidence interval; Trt = treatment. 
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Table S3 Relationship between HRV and individual components of the lifestyle-score 
SDNN, high and low frequency were transformed to z-scores. Data are β coefficients (95% confidence Interval) per 1-unit increase of the respective variable and 
adjusted for sex, age, alcohol consumption, educational status, family history of cardiovascular disease. SDNN = standard deviation of all normal RR intervals; 
BMI = body mass index; Regular physical activity = ≥75 or 150 minutes per week of vigorous or moderate physical activity; Healthy diet = ≥2 diet components 
achieved; Healthy blood pressure level = systolic and diastolic blood pressure <120 and 80mmHg without treatment; Healthy cholesterol level = total cholesterol 
<200mg/dl; Healthy HbA1c = glycated hemoglobin A1c <5.7%.  
n=2079 SDNN High frequency Low Frequency 
Never smoking 0.13 (0.04; 0.21), p=0.003 0.12 (0.04; 0.20), p=0.004 0.18 (0.10; 0.26), p<0.0001 
BMI <25kg/m2 0.25 (0.16; 0.34), p<0.0001 0.15 (0.06; 0.24), p=0.001 0.17 (0.08; 0.25), p=0.0001 
Regular physical activity 0.30 (0.20; 0.41), p<0.0001 0.09 (-0.008; 0.20), p=0.07 0.09 (-0.01; 0.19), p=0.08 
Healthy diet  -0.005 (-0.21; 0.20), p=0.96 -0.07 (-0.27; 0.13), p=0.50 -0.16 (-0.35; 0.04), p=0.11 
Healthy blood pressure level 0.11 (0.02; 0.21), p=0.02 0.18 (0.09; 0.28), p=0.0002 0.12 (0.03; 0.22), p=0.007 
Healthy cholesterol level 0.11 (0.02; 0.20), p=0.02 0.11 (0.02; 0.20), p=0.02 0.10 (0.02; 0.19), p=0.02 
Healthy HbA1c -0.04 (-0.13; 0.06), p=0.47 0.05 (-0.04; 0.15), p=0.29 0.08 (-0.01; 0.17), p=0.08 
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Figure S1 Relationship between heart rate variability and lifestyle-score 
 
0.14
0.12 0.12
0.07
0.06 0.06
0.04
0.02
0.03
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
SDNN High Frequency Low Frequency
β
 
c
o
e
f
f
i
c
i
e
n
t
 
(
9
5
%
 
C
o
n
f
i
d
e
n
c
e
 
I
n
t
e
r
v
a
l
)
Model 1
Model 2
Model 3
5.MANUSCRIPT 2 – HRV and sleep-related breathing disorders 
 
33 
5.MANUSCRIPT 2 – HRV and sleep-related breathing disorders 
 
Heart rate variability and sleep-related breathing disorders in the general 
population 
 
Stefanie Aeschbacher, Matthias Bossard, Tobias Schoen, Delia Schmidlin, Christoph Muff, 
Anna Maseli, Jörg D Leuppi, David Miedinger, Nicole M Probst-Hensch, Arno Schmidt-
Trucksäss, Martin Risch, Lorenz Risch, David Conen 
 
 
CURRENT STANDING: IN REVISION  
  
5.MANUSCRIPT 2 – HRV and sleep-related breathing disorders 
 
34 
Heart rate variability and sleep-related breathing disorders in the 
general population 
 
Stefanie Aeschbacher1,2, Matthias Bossard2,3 Tobias Schoen2,3, Delia Schmidlin2, Christoph 
Muff,1,2 Anna Maseli1,2, Jörg D Leuppi4, David Miedinger4, Nicole M Probst-Hensch5, Arno 
Schmidt-Trucksäss6, Martin Risch7,8, Lorenz Risch7,9,10, David Conen1,2 
 
1. Division of Internal Medicine, Department of Medicine, University Hospital Basel, 
4031 Basel, Switzerland 
2. Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, 4056 
Basel, Switzerland 
3. Cardiology Division, Department of Medicine, University Hospital Basel, 4031 
Basel, Switzerland 
4. Medical University Clinic, Cantonal Hospital Baselland, 4410 Liestal, Switzerland 
5. Swiss Tropical and Public Health Institute, and the University of Basel, 4051 
Basel, Switzerland  
6. Department of Sport, Exercise and Health, Division Sports and Exercise Medicine, 
University of Basel, 4052 Basel, Switzerland  
7. Labormedizinisches Zentrum Dr. Risch, 9494 Schaan, Principality of Liechtenstein 
8. Division of Laboratory Medicine, Kantonsspital Graubünden, 7000 Chur, 
Switzerland 
9. Division of Clinical Biochemistry, Medical University, 6020 Innsbruck, Austria 
10. Private University, 9495 Triesen, Principality of Liechtenstein 
 
Short title: HRV and sleep-related breathing disorders 
Word count (total): 4782 
 
Address for correspondence: 
David Conen MD MPH  
Department of Medicine, University Hospital Basel  
Petersgraben 4, 4031 Basel, Switzerland 
Phone: +41 61 328 66 96; Fax +41 61 265 57 34  
E-mail: david.conen@usb.ch 
  
5.MANUSCRIPT 2 – HRV and sleep-related breathing disorders 
 
35 
Abstract 
Background: Obstructive sleep apnea seems to have an important influence on the 
autonomic nervous system. In this study, we assessed the relationships of sleep apnea 
related parameters with 24-hour (h) heart rate variability (HRV) in a large population of young 
and healthy adults. 
Methods: Participants aged 25-41 years with a BMI <35kg/m2 and without known obstructive 
sleep apnea were included in a prospective population-based cohort study. HRV was 
assessed using 24-h ECG monitoring. The standard deviation of all normal RR intervals 
(SDNN) was used as main HRV variable. Apnea-hypopnea index (AHI) and oxygen 
desaturation index (ODI) were obtained from nighttime pulse oximetry with nasal airflow 
measurements. We defined sleep-related breathing disorders as an AHI≥5 or an ODI≥5. 
Multivariable regression models were constructed to assess the relationship of HRV with 
either AHI or ODI.  
Results: Median age of the 1255 participants was 37 years, 47% were male and 9.6% had 
an AHI≥5. Linear inverse association of SDNN across AHI and ODI groups were found (p for 
trend=0.006 and 0.0004, respectively). The β-coefficient (95% confidence interval) for the 
relationship between SDNN and elevated AHI was -0.20 (-0.40;-0.11), p=0.04 and -0.29 (-
0.47;-0.11), p=0.002 for elevated ODI. After adjustment for 24-h heart rate (HR), the same β-
coefficients (95%CI) were -0.06 (-0.22; 0.11), p=0.51 and -0.14 (-0.30; 0.01), p=0.07, 
respectively.  
Conclusion: Even early stages of sleep-related breathing disorders are inversely associated 
with HRV in young and healthy adults, suggesting that they are tightly linked with autonomic 
dysfunction. However, the incremental information beyond HR is minimal.  
 
Keywords: Heart rate variability, sleep-related breathing disorders, population-based, 
general population  
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Introduction 
Sleep-related breathing disorders, such as obstructive sleep apnea (OSA), are highly 
prevalent and remain often undiagnosed.1-3 OSA is independently associated with an 
increased risk of hypertension, coronary artery disease, and sudden death.4-10 Treatment of 
sleep-related breathing disorders can effectively lower the risk for adverse cardiovascular 
outcomes.11,12  
The autonomic nervous system is involved in numerous physiologic processes of the 
cardiovascular system.13 Heart rate variability (HRV) is a validated and easily obtainable 
measure of the influence of autonomic function on the heart and by itself associated with 
cardiovascular risk factors and mortality.14-16 An experimental study showed markedly higher 
sympathetic nerve activity among OSA patients without treatment compared to treated 
patients.17 Another small study has found a worse HRV profile and an increased heart rate 
(HR) directly after an apnea.18 An unbalanced autonomic function among patients with 
manifest OSA could therefore be one potential reason for their increased cardiovascular risk.  
Population-based studies assessing the relationship of the autonomic nervous function with 
OSA are scarce and the shape of the relationship is currently unknown. In addition, it is 
unclear whether autonomic function is altered influenced by sleep-related breathing disorders 
among otherwise asymptomatic individuals with subclinical sleep-related breathing disorders. 
Finally, HR by itself is an independent risk factor for cardiovascular events,19 seems to be 
modified among OSA patients,18 and is tightly linked with HRV.20 In this context, it is unknown 
whether HRV contains any additional information beyond HR. 
In order to address some of these issues, we evaluated the association of HRV with several 
sleep-apnea related parameters in a large cohort of young and healthy adults from the 
general population.   
5.MANUSCRIPT 2 – HRV and sleep-related breathing disorders 
 
37 
Methods 
Study population 
Between 2010 and 2013 inhabitants of the Principality of Liechtenstein aged between 25 to 
41 years were invited to participate in the ‘genetic and phenotypic determinants of blood 
pressure and other cardiovascular risk factors’ (GAPP) study, a prospective population-
based cohort study. Study design and methodology have been published previously.21 Study 
exclusion criteria were known OSA, renal failure, current intake of antidiabetic drugs, a body 
mass index (BMI) >35kg/m2, established cardiovascular disease or other severe illnesses. Of 
the 2170 participants enrolled, 1410 participants performed a nighttime pulse oximetry and 
nasal flow measurement. Of these, participants were excluded if the sleep study duration 
was <180 minutes (n=114) or if they had missing or incomplete 24-hour (h) 
electrocardiogram (ECG) recordings (n=19) or other missing covariates (n=22), leaving 1255 
participants for the current analysis. Written informed consent was obtained from every 
participant and the study protocol was approved by the local ethics committee.  
 
24-hour electrocardiogram 
Every participant underwent a 24-h three-channel Holter ECG recording with a validated 
device (AR12plus, Schiller AG, Switzerland). When the ECG monitoring duration was <80% 
of the target time (i.e. <19.2 hours), the study was repeated whenever possible. ECG devices 
were started in the morning after the study examination. All Holter studies were post-
processed using a dedicated Software (MediLog Darwin V2, Schiller AG, Switzerland) to 
remove artefacts and redefine premature ventricular and atrial beats. Time- and frequency 
domain HRV and mean HR were automatically calculated by the software. The standard 
deviation of all normal RR intervals (SDNN) was pre-defined to be the main HRV variable. In 
addition, low frequency (LF), high frequency (HF) and total power (TP) were used for this 
analysis. LF and HF were normalized, by calculating LF/(TP-VLF)*100 and HF/(TP-
VLF)*100, respectively.  
 
Nighttime pulse oximetry with nasal flow measurement 
Nighttime pulse oximetry with nasal flow measurement was performed in every participant 
using a validated device (ApneaLink, ResMed, USA).22 Participants were instructed to place 
the nasal flow cannula and the finger pulse oximetry probe, to start the device before falling 
asleep and to stop the measurement when waking up in the morning. Recording length had 
to be at least 180 minutes for both nasal airflow measurement and pulse oximetry, otherwise 
participants were asked to repeat the measurement.  
Apnea-hypopnea index (AHI) was defined as the average number of apnea and hypopnea 
episodes per hour of sleep. An apnea was defined as a nasal airflow reduction of at least 
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80% during ≥10 seconds.23 A hypopnea was defined as a nasal airflow reduction of ≥30% 
with a concomitant fall in oxygen saturation of ≥4%. Oxygen desaturation index (ODI) was 
defined as the mean number of oxygen desaturations of ≥4% per hour of recording.23 Sleep-
related breathing disorders were defined as an AHI ≥5 or an ODI ≥5. 
 
Assessment of other study variables 
Questionnaires were used to obtain information about personal, medical, lifestyle and 
nutritional factors. Smoking status was self-assessed and classified as never, past or current 
smoker. Physical activity was assessed using the International Physical Activity 
Questionnaire (IPAQ)24 and regular physical activity was defined as ≥150 minutes of 
moderate activity or ≥75 minutes of vigorous activity per week. Information about fruit and 
vegetable consumption was dichotomized into ≥5 versus <5 servings per day. Highest 
educational status achieved was self-reported and classified into the categories high school, 
college and university degree. Daytime sleepiness was assessed using the Epworth 
Sleepiness Scale (ESS) questionnaire.25 Height and weight were measured in a standardized 
way by trained study nurses. BMI was calculated as body weight in kilogram divided by 
height in meters squared. Office blood pressure was measured in a sitting position after 5 
minutes of rest. Three blood pressure measurements were performed. For the current 
analysis the mean of the second and third measurement was used. Low-density lipoprotein 
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), glycated hemoglobin A1c 
(HbA1c), creatinine and copeptin were measured from a fasting venous blood sample 
immediately after the blood draw according to standard methodology.21 Estimated glomerular 
filtration rate was calculated using the creatinine based chronic kidney disease epidemiology 
collaboration (CKD-EPI) formula.26  
 
Statistical analyses 
Baseline characteristics were stratified according the presence or absence of an AHI ≥5. 
Distribution of continuous variables was checked using skewness, kurtosis and visual 
inspection of the histogram. Continuous variables were presented as medians (interquartile 
ranges) and categorical variables as numbers (percentages). Group comparisons were done 
using Wilcoxon rank sum tests or Chi-square tests, as appropriate.  
To evaluate the relationship of AHI or ODI with HRV, separate multivariable linear regression 
models were constructed using different HRV variables as the dependent variable. To 
assess the linearity of the relationships with HRV, AHI and ODI were categorized into 0 
(reference category), 1, 2, 3-4 and ≥5 episodes per hour. LF, HF and TP were log-
transformed. All HRV variables were converted into z-scores to improve comparability. All 
models were adjusted for a predefined set of covariates, including sex, age, BMI, current 
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smoking, LDL-C, HDL-C, copeptin, prediabetes, systolic blood pressure, eGFR, regular 
physical activity, fruit and vegetable consumption and educational status.  
We also evaluated the association of HR with sleep-related breathing disorders in similar 
models described above. In order to evaluate the incremental information of HRV beyond 
HR, all HRV based models were additionally adjusted for resting and 24-h heart rate in a 
separate step.  
To assess potential effect modification of the relationship of HRV with sleep-related breathing 
disorders, pre-specified subgroup analyses for sex, smoking, BMI, age and physical activity 
were performed. Multiplicative interaction terms were entered in the non-stratified models to 
evaluate significant subgroup effects. A p-value <0.05 was pre-specified to indicate statistical 
significance. SAS version 9.4 (SAS Institute Inc, Cary, North Carolina, USA) was used for all 
analyses.  
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Results 
Baseline characteristics stratified by the presence or absence of an AHI≥5 are shown in 
Table 1. Overall 120 (9.6%) participants had an AHI≥5, 83% of them were male. Compared 
to participants with a normal AHI, participants with an AHI≥5 had a higher BMI (27 versus 24 
kg/m2, p<0.0001), were more often current smokers (29 versus 21%, p=0.04) and had a 
higher blood pressure (128 versus 120 mmHg for systolic, and 85 versus 78 mmHg for 
diastolic blood pressure, p<0.0001 for both comparisons). The ESS was not significantly 
different among both groups (median score 7 versus 7, p=0.38). SDNN and HF were lower 
among participants with an AHI ≥5 (147 versus 151 ms, p=0.04 and 12.7 versus 15.5 ms2, 
p=0.002, respectively). Normalized LF and TP did not differ between the two groups.  
 
Relationship of heart rate variability with sleep apnea related parameters  
The relationships between HRV categories and AHI are shown in Table 2. After multivariable 
adjustment SDNN significantly decreased across increasing AHI categories (p for 
trend=0.006). There was no significant relationship of AHI with normalized LF, normalized HF 
and TP. Additional adjustment for resting and 24-h HR attenuated these relationships. 
Similar findings were obtained when AHI categories were replaced by ODI categories, as 
shown in Table 3. After multivariable adjustment we found significant inverse relationships for 
SDNN and TP (all p for trend <0.05) and a positive association with normalized LF (p for 
trend =0.02). After additional adjustment for either resting of 24-h HR, only SDNN remained 
linearly associated with ODI (p for trend = 0.006 and 0.03, respectively) (Table 3). Similar 
findings were also obtained, when the AHI or ODI were entered into the models as 
dichotomous variable (≥5 versus <5), as shown in Table 4.  
Subgroup analyses are presented in Table S1. These analyses suggest that the relationships 
of HRV with both AHI and ODI are stronger among current smokers compared with non-
current smokers. None of the other p values for interaction were statistically significant.  
 
Relationship of heart rate with sleep apnea related parameters  
The results for the relationships of either resting or 24-h HR with AHI and ODI are presented 
in Table S2 and S3. AHI and ODI categories were significantly related to resting and 24-h HR 
after multivariable adjustment. Additional adjustment for SDNN attenuated these 
relationships, however the associations for both AHI and ODI with ambulatory HR remained 
statistically significant (Tables S2 and S3).  
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Discussion 
In this large population based cohort of young and healthy adults we found significant 
relationships of HRV with both AHI and ODI after comprehensive multivariable adjustment. 
These associations were found to be linear without evidence of a threshold. Our data 
therefore suggest a link between subclinical sleep-related breathing disorders and autonomic 
dysfunction, which may contribute to the unfavorable outcome of patients with overt OSA. As 
an additional finding we observed that the relationships of sleep-related breathing disorder 
with SDNN became strongly attenuated after additional adjustment for resting and mainly 24-
h HR. Thus, HRV parameters do not seem to provide a significant amount of additional 
information beyond HR.20 This is an important finding, as the quantification of HR, in 
particular resting HR, is much easier than the quantification of 24-h HRV.  
Overall, around 10% of this young and healthy population without overt OSA had an AHI or 
ODI ≥5, and men were more often affected compared to women. This is in line with at least 
one prior population-based study showing an OSA prevalence of around 20% in a middle-
aged population.1 In our population, the ESS was similar among both groups, suggesting that 
affected individuals in our study may be at an early, still asymptomatic stage of the disorder. 
Nevertheless, our findings suggest that autonomic dysfunction could be an early 
phenomenon already present among otherwise healthy individuals with subclinical disease. 
Prospective follow-up of the GAPP cohort will shed more light on the course of this potential 
public health problem. At the current stage, lifestyle modification in affected individuals 
seems prudent, given the strong correlation between BMI and sleep-related breathing 
disorders and the stronger relationship with HRV observed among current smokers. 27,28  
Our results showed linear associations of AHI and ODI with markers of the HRV, such as the 
SDNN and TP, which are corresponding to total variability.16 Those variables might detect 
early effects of sleep-related breathing disorders on the autonomic function. Normalized LF, 
partly modulated by sympathetic activity, was linearly increasing with increasing ODI but not 
AHI. These results are supported by another study, showing higher sympathetic nerve 
activity among untreated compared to treated OSA patients.17 According to our results, 
normalized HF, which is controlled by parasympathetic activity, was not significantly 
associated with sleep apnea-related variables. Our results might therefore reflect increased 
sympathetic but not reduced parasympathetic activity among participants with a higher 
number of apneas and desaturations.  
Similar to HRV we found strong relationships of resting and 24-h HR with AHI and ODI, with 
a stronger association for 24-h HR compared with resting HR. Even though HR is strongly 
influenced by various factors, HR is also linked to the autonomic nervous system.29 A recent 
study has confirmed the tight link between HR and HRV, suggesting that these variables 
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should not be assessed independent of each other.20 Further studies are needed to evaluate 
the effect of HRV that is independent of HR.  
 
Strengths and limitations:  
Strengths of this study were the population-based study design, the well-characterized young 
population and the availability of 24-h HRV in the entire study population. However several 
potential limitations have to be taken into account in the interpretation of our results. First, 
mainly white people were included in the GAPP study, and the generalizability of our results 
to other population samples is unclear. Second, this is a cross-sectional analysis and 
therefore the directionality of our associations as well as their causality remain unknown. 
Finally, polysomnography as a gold standard for diagnosing OSA was not available in our 
population. However, previous studies have shown excellent sensitivity and specificity of 
nighttime pulse oximetry with nasal flow measurement for this purpose.22  
 
Conclusion:  
Almost 10% of this young and healthy population without known OSA had increased AHI or 
ODI levels. Increasing levels of AHI and ODI were significantly associated with a decreasing 
HRV. Our results therefore suggest that even subclinical stages of sleep-related breathing 
disorders are associated with autonomic dysfunction. This relationship was particularly 
strong among smokers. Our results also show that the incremental information of HRV 
parameters beyond 24-h HR is minimal. Further studies are needed to better assess the role 
of autonomic dysfunction in the development of cardiovascular disease among patients with 
clinical and subclinical sleep-related breathing disorders.  
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Table 1 Baseline Characteristics stratified by apnea-hypopnea index 
n=1255 
AHI < 5 
n=1135 (90.4%) 
AHI ≥ 5 
n=120 (9.6%) p-value 
Age, years 35 (30; 39) 38 (33; 40) 0.001 
Male sex, % 492 (43.4) 100 (83.3) <0.0001 
Smoking, % 
  
0.08 
Current 238 (21.0) 35 (29.2) 
 
Past 260 (22.9) 29 (24.1) 
 
never 637 (56.1) 56 (46.7) 
 
BMI, kg/m2 23.9 (21.9; 26.5) 27.4 (24.5; 30.9) <0.0001 
Systolic BP, mmHg 120 (111; 127) 128 (120; 134) <0.0001 
Diastolic BP, mmHg 78 (73; 84) 85 (79; 89) <0.0001 
Hypertension, % 142 (12.5)  33 (27.5) <0.0001 
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LDL-C, mmol/l 2.85 (2.33; 3.44) 3.34 (2.75; 3.92) <0.0001 
HDL-C, mmol/l 1.53 (1.27; 1.79) 1.22 (1.02; 1.48) <0.0001 
Prediabetes, % 244 (21.5) 38 (31.7) <0.0001 
Hs-CRP, mmol/l 1.0 (0.5; 2.0) 1.5 (0.6; 3.2) 0.002 
Education, % 
  
0.01 
High school 81 (7.1) 18 (15.0) 
 
College 629 (55.4) 60 (50.0) 
 
University degree 425 (37.4) 42 (35.0) 
 
AHI 1 (0; 2) 8 (6; 12) <0.0001 
ODI 1 (0; 2) 9 (6; 13) <0.0001 
ODI≥5 36 (3.2) 105 (87.5) <0.0001 
Epworth Sleepiness Scale 7 (5;10) 7 (5; 11) 0.38 
Epworth Sleepiness Scale ≥11 221 (19.5) 30 (25.0) 0.15 
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Heart Rate Variability 
   
Resting heart rate, bpm 61 (56; 67) 63 (58; 68) 0.04 
Ambulatory heart rate, bpm 74 (69; 80) 76 (71; 82) 0.09 
SDNN, ms 151.3 (128.3; 177.7) 147.1 (118.2; 170.4) 0.04 
High frequency nu, ms/s2 15.5 (11.4; 19.9) 12.7 (9.1; 17.4) 0.002 
Low frequency nu, ms/s2 53.6 (47.5; 59.0) 56.8 (51.2; 61.9) 0.55 
Total power 3625 (2502; 5058) 3459 (2119; 4887) 0.12 
Data are median (interquartile range) or number (percentage). P-value was calculated using Wilcoxon Rank Sum Test or Chi-square Test, as appropriate. 
Hypertension was defined as a systolic or diastolic blood pressure ≥140 or ≥90mmHg or intake of antihypertensive treatment. Prediabetes was defined as a 
glycated hemoglobin A1c >5.6%. AHI = Apnea-hypopnea index; ODI = oxygen desaturation index; BMI = body mass index; BP = blood pressure; LDL-C = low 
densitiy lipoprotein cholesterol; HDL-C = high density lipoprotein cholesterol; hs-CRP = high sensitivity C - reactive protein; SDNN = standard deviation of all 
normal RR intervals.  
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Table 2 Relationship of heart rate variability with categories of the apnea-hypopnea index  
 
 AHI 0 
n= 388 
AHI 1 
n= 397 
AHI 2 
n= 204 
AHI 3-4 
n= 146 
AHI≥5 
n= 120 p-value 
SDNN 
Model 1 
Ref. 
-0.06 (-0.19; 0.08) -0.07 (-0.24; 0.10) -0.22 (-0.41; -0.02) -0.29 (-0.50; -0.07) 0.006 
Model 2 -0.06 (-0.18; 0.06) -0.06 (-0.21; 0.09) -0.16 (-0.33; 0.02) -0.17 (-0.37; 0.02) 0.04 
Model 3 -0.03 (-0.15; 0.09) 0.00 (-0.15; 0.15) -0.11 (-0.28; 0.05) -0.09 (-0.28; 0.10) 0.23 
LFnu 
Model 1 
Ref. 
0.08 (-0.05; 0.21) 0.18 (0.01; 0.34) 0.24 (0.05; 0.43) 0.14 (-0.07; 0.36) 0.17 
Model 2 0.08 (-0.05; 0.21) 0.17 (0.01; 0.34) 0.22 (0.03; 0.40) 0.10 (-0.11; 0.31) 0.05 
Model 3 0.07 (-0.06; 0.20) 0.14 (-0.02; 0.30) 0.19 (-0.00; 0.37) 0.04 (-0.17; 0.25) 0.17 
HFnu 
Model 1 
Ref. 
-0.03 (-0.17; 0.10) -0.13 (-0.30; 0.03) 0.02 (-0.17; 0.21) -0.05 (-0.27; 0.16) 0.63 
Model 2 -0.03 (-0.16; 0.10) -0.13 (-0.29; 0.04) 0.05 (-0.14; 0.23) -0.005 (-0.21; 0.20) 0.88 
Model 3 -0.01 (-0.14; 0.11) -0.09 (-0.24; 0.07) 0.09 (-0.10; 0.27) 0.08 (-0.13; 0.28) 0.44 
TP 
Model 1 
Ref. 
0.04 (-0.09; 0.17) -0.06 (-0.22; 0.10) -0.05 (-0.24; 0.13) -0.19 (-0.40; 0.01) 0.06 
Model 2 0.04 (-0.07; 0.15) -0.05 (-0.18; 0.09) 0.01 (-0.14; 0.17) -0.07 (-0.25; 0.10) 0.31 
Model 3 0.07 (-0.03; 0.17) 0.02 (-0.10; 0.14) 0.07 (-0.07; 0.21) 0.04 (-0.11; 0.20) 0.75 
Data are β-coefficients (95%CI). Model 1 was adjusted for sex, age, body mass index, current smoking, low densitiy lipoprotein, high densitiy lipoprotein, 
prediabetes, systolic blood pressure, glomerular filtration rate, physical activity, fruit and vegetable intake and copeptin. Model 2 was additionally adjusted for 
resting heart rate. Model 3 was additionally adjusted for ambulatory HR instead of resting HR. HRV variables were transfomed to z-scores. SDNN = standard 
deviation of all normal RR intervals, LFnu = low frequency normalized units; HFnu = high frequency normalized units; TP = total power; Ref= Reference; AHI = 
Apnea-hypopnea index. n=1255.  
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Table 3 Relationship of heart rate variability with categories of the oxygen desaturation index  
 
 ODI 0 
n= 377 
ODI 1 
n= 360 
ODI 2 
n= 195 
ODI 3-4 
n= 182 
ODI ≥5 
n= 141 p-value 
SDNN 
Model 1 
Ref. 
-0.003 (-0.14; 0.14) -0.06 (-0.24; 0.11) -0.20 (-0.39; -0.01) -0.37 (-0.58; -0.16) 0.0004 
Model 2 
-0.003 (-0.12; 0.12) -0.05 (-0.20; 0.11) -0.15 (-0.31; 0.02) -0.25 (-0.44; -0.06) 0.006 
Model 3 
-0.009 (-0.13; 0.11) -0.05 (-0.20; 0.11) -0.12 (-0.28; 0.04) -0.19 (-0.38; -0.009) 0.03 
LFnu 
Model 1 
Ref. 
0.11 (-0.02; 0.25) 0.06 (-0.11; 0.23) 0.17 (-0.01; 0.36) 0.26 (0.05; 0.47) 0.02 
Model 2 0.11 (-0.02; 0.24) 0.06 (-0.11; 0.23) 0.15 (-0.02; 0.34) 0.22 (0.01; 0.43) 0.06 
Model 3 0.12 (-0.01; 0.25) 0.05 (-0.11; 0.22) 0.13 (-0.05; 0.31) 0.17 (-0.04; 0.37) 0.17 
HFnu 
Model 1 
Ref. 
-0.06 (-0.19; 0.08) -0.09 (-0.26; 0.08) 0.008 (-0.18; 0.19) -0.17 (-0.38; 0.04) 0.14 
Model 2 
-0.06 (-0.19; 0.08) -0.08 (-0.25 ; 0.09) 0.03 (-0.15; 0.21) -0.12 (-0.33; 0.08) 0.33 
Model 3 
-0.06 (-0.19; 0.07) -0.08 (-0.24; 0.09) 0.06 (-0.11; 0.24) -0.06 (-0.26; 0.14) 0.99 
TP 
Model 1 
Ref. 
0.06 (-0.07; 0.19) 0.04 (-0.13; 0.20) 0.01 (-0.17; 0.19) -0.17 (-0.37; 0.04) 0.05 
Model 2 0.06 (-0.05; 0.17) 0.05 (-0.08; 0.19) 0.07 (-0.08; 0.22) -0.04 (-0.21; 0.13) 0.48 
Model 3 0.05 (-0.05; 0.15) 0.06 (-0.07; 0.19) 0.11 (-0.02; 0.25) 0.05 (-0.11; 0.21) 0.62 
Data are β-coefficients (95%CI). Model 1 was adjusted for sex, age, body mass index, current smoking, low densitiy lipoprotein, high densitiy lipoprotein, 
prediabetes, systolic blood pressure, glomerular filtration rate, physical activity, fruit and vegetable intake and copeptin. Model 2 was additionally adjusted for 
resting heart rate. Model 3 was additionally adjusted for ambulatory HR instead of resting HR. HRV variables were transfomed to z-scores. SDNN = standard 
deviation of all normal RR intervals, LFnu = low frequency normalized units; HFnu = high frequency normalized units; TP = total power; Ref= Reference; ODI = 
oxygen desaturation index. n=1255. 
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Table 4 Relationship between heart rate variability and apnea-hypopnea index or oxygen desaturation index 
Data are β-coefficients (95%CI). Model 1 was adjusted for sex, age, body mass index, current smoking, low densitiy lipoprotein, high densitiy lipoprotein, 
prediabetes, systolic blood pressure, glomerular filtration rate, physical activity, fruit and vegetable intake and copeptin. Model 2 was additionally adjusted for 
resting heart rate. Model 3 was additionally adjusted for ambulatory HR instead of resting HR. HRV variables were transfomed to z-scores. SDNN = standard 
deviation of all normal RR intervals, LFnu = low frequency normalized units; HFnu = high frequency normalized units; TP = total power; Ref= Reference; AHI = 
Apnea-Hypopnea Index. n=1255. 
  AHI≥5 p-value ODI≥5 p-value 
SDNN 
Model 1 -0.20 (-0.40; -0.11) 0.04 -0.29 (-0.47; -0.11) 0.002 
Model 2 -0.11 (-0.28; 0.06) 0.21 -0.19 (-0.35; -0.03) 0.02 
Model 3 -0.06 (-0.22; 0.11) 0.51 -0.14 (-0.30; 0.01) 0.07 
LFnu 
Model 1 0.02 (-0.17; 0.20) 0.85 0.16 (-0.02; 0.33) 0.08 
Model 2 -0.02 (-0.20; 0.17) 0.85 0.12 (-0.05; 0.30) 0.18 
Model 3 -0.06 (-0.24; 0.12) 0.52 0.08 (-0.09; 0.25) 0.37 
HFnu 
Model 1 -0.01 (-0.20; 0.17) 0.89 -0.14 (-0.31; 0.04) 0.13 
Model 2 0.03 (-0.16; 0.21) 0.77 -0.10 (-0.27; 0.08) 0.28 
Model 3 0.08 (-0.09; 0.26) 0.36 -0.04 (-0.21; 0.13) 0.63 
TP 
Model 1 -0.18 (-0.36; -0.002) 0.05 -0.20 (-0.37; -0.03) 0.02 
Model 2 -0.08 (-0.23; 0.07) 0.31 -0.09 (-0.24; 0.05) 0.21 
Model 3 -0.003 (-0.14; 0.14) 0.97 -0.02 (-0.15; 0.12) 0.81 
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Table S1 Subgroup analyses of the relationship between the Apnea Hypopnea Index and the SDNN 
SDNN  n AHI pathologic p-value for interaction ODI pathologic 
p-value for 
interaction 
Sex 
Men 592 -0.16 (-0.37; 0.06) 
0.28 
-0.24 (-0.44; -0.04) 
0.42 
Women 663 -0.06 (-0.48; 0.36) -0.21 (-0.63; 0.21) 
Smoking 
Current 273 -0.35 (-0.70; -0.003) 
0.01 
-0.66 (-1.01; -0.31) 
0.0009 
Past/never 982 -0.06 (-0.28; 0.16) -0.11 (-0.32; 0.10) 
BMI 
<25 729 -0.32 (-0.66; 0.02) 
0.52 
-0.30 (-0.64; 0.05) 
0.86 
>= 25 526 -0.13 (-0.36; 0.09) -0.27 (-0.47; -0.06) 
Age 
<35 628 -0.35 (-0.66; -0.03) 
0.59 
-0.40 (-0.70; -0.10) 
0.62 
>=35 627 -0.07 (-0.30; 0.16) -0.18 (-0.34; 0.05) 
Regular physical 
activity  
Yes 876 -0.15 (-0.39; 0.09) 
0.14 
-0.32 (-0.54; -0.10) 
0.68 
No 379 -0.37 (-0.67; -0.07) -0.33 (-0.63; -0.02) 
Data are presented as β-coefficients (95% confidence interval). Multivariable model was adjusted for sex, age, body mass index, smoking status, low densitiy 
lipoprotein, high densitiy lipoprotein, prediabetes systolic blood pressure, glomerular filtration rate, physical activity, fruit and vegetable intake and copeptin. HRV 
variables were transformed to z-scores. SDNN= standard deviation of all normal RR intervals. Regular physical activity was defined as vigorous activity ≥75 
minutes/week or moderate activity ≥150 minutes per week. 
  
5.MANUSCRIPT 2 – HRV and sleep-related breathing disorders 
 
54 
Table S2 Relationship of heart rate with apnea-hypopnea Index  
 AHI ≥5 AHI 0 
n= 388 
AHI 1 
n= 397 
AHI 2 
n= 204 
AHI 3-4 
n= 146 
AHI≥5 
n= 120 p-value 
 Resting Heart Rate 
Model 1 0.21 (0.02; 0.40), p=0.03 
Ref. 
-0.00 (-0.14; 0.14) 0.03 (-0.14; 0.20) 0.14 (-0.06; 0.33) 0.24 (0.03; 0.46) 0.01 
Model 2 0.12 (-0.05; 0.29), p=0.18 -0.03 (-0.15; 0.10) -0.002 (-0.16; 0.10) 0.04 (-0.14; 0.21) 0.11 (-0.08; 0.31) 0.18 
 Ambulatory Heart Rate 
Model 1 0.28 (0.10; 0.46), p=0.002 
Ref. 
0.05 (-0.08; 0.18) 0.13 (-0.03; 0.30) 0.20 (0.008; 0.38) 0.38 (0.17; 0.58) 0.0002 
Model 2 0.19 (0.03; 0.34), p=0.02 0.02 (-0.09; 0.14) 0.10 (-0.04; 0.24) 0.09 (-0.07; 0.26) 0.24 (0.06; 0.42) 0.007 
Data are β-coefficients (95%CI). Model 1 was adjusted for sex, age, body mass index, current smoking, low density lipoprotein, high density lipoprotein, 
prediabetes systolic blood pressure, glomerular filtration rate, physical activity, fruit and vegetable intake and copeptin. Model 2 was additionally adjusted for the 
standard deviation of all normal RR intervals. HR was transformed to z-scores. AHI = Apnea-hypopnea index  
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Table S3 Relationship of heart rate with oxygen desaturation index 
 ODI ≥5 ODI 0 
n= 377 
ODI 1 
n= 360 
ODI 2 
n= 195 
ODI 3-4 
n= 182 
ODI ≥5 
n= 141 p-value 
 Resting Heart Rate 
Model 1 0.21 (0.03; 0.40), p=0.02 
Ref. 
-0.00 (-0.14; 0.14) 0.03 (-0.14; 0.21) 0.12 (-0.07; 0.21) 0.26 (0.04; 0.48) 0.03 
Model 2 0.08 (-0.08; 0.24), p=0.33 -0.002 (-0.13; 0.12) 0.005 (-0.15; 0.16) 0.03 (-0.14; 0.20) -0.09 (-0.10; 0.28) 0.32 
 Ambulatory Heart Rate 
Model 1 0.29 (0.11; 0.46), p=0.001 
Ref. 
-0.01 (-0.15; 0.12) 0.04 (-0.13; 0.21) 0.16 (-0.02; 0.34) 0.34 (0.14; 0.54) 0.0003 
Model 2 0.15 (-0.00; 0.30), p=0.05 -0.01 (-0.13; 0.10) 0.007 (-0.14; 0.15) 0.06 (-0.09; 0.22) 0.17 (-0.01; 0.35) 0.04 
Data are β-coefficients (95%CI). Model 1 was adjusted for sex, age, body mass index, current smoking, low densitiy lipoprotein, high densitiy lipoprotein, 
prediabetes systolic blood pressure, glomerular filtration rate, physical activity, fruit and vegetable intake and copeptin. Model 2 was additionally adjusted for the 
standard deviation of all normal RR intervals. HR was transformed to z-scores. ODI = oxygen desaturation index. 
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Abstract 
Background: Heart rate (HR), heart rate variability (HRV) and inflammation are all associated 
with cardiovascular morbidity and mortality. The aim of this study was to assess potential 
interrelationships between these parameters in a population of young and healthy adults.  
Methods and Results: Individuals aged 25-41 years without established cardiovascular 
disease were included in a prospective population-based study. All participants underwent 
24-hour electrocardiography using a validated device. The standard deviation of all normal 
RR intervals (SDNN) was pre-defined as the main HRV outcome variable. High-sensitivity C-
reactive protein (hs-CRP), total leukocyte (LC) count and LC subtypes were obtained from 
venous blood samples. Multivariable linear regression models were constructed to assess 
the relationships of inflammatory biomarkers with HRV and HR. Overall, 2064 participants 
(47% men, median age 37years) were included in this analysis. In multivariable linear 
regression analyses using SDNN as the outcome variable, β-coefficients (95% confidence 
intervals) per 1 standard deviation (SD) increase on the log-scale were -0.11 (-0.16;-0.07), 
p<0.0001 for hs-CRP, -0.13 (-0.17;-0.09), p<0.0001 for total LC count, -0.12 (-0.16;-0.08), 
p<0.0001 for neutrophils, -0.04 (-0.09;0.00), p=0.05 for lymphocytes and -0.08 (-0.09;-0.02), 
p=0.005 for monocytes. Multivariable adjusted β-coefficients (95%CI) for 24-hour HR were 
0.68 (0.30;1.07), p=0.0005 for hs-CRP, 1.21 (0.83;1.58), p<0.0001 for LC, 1.38 (1.01;1.75), 
p<0.0001 for neutrophils, -0.19 (-0.57;0.19), p=0.32 for lymphocytes and 0.66 (0.28;1.04), 
p=0.0007 for monocytes. 
Conclusion: In this large cohort of young and healthy adults, inflammatory parameters were 
strongly associated with increased HR and decreased HRV, suggesting an important 
interaction between inflammatory pathways and the autonomic nervous system.  
Keywords: heart rate variability, heart rate, inflammation, high-sensitivity C-reactive protein, 
leukocytes 
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Introduction 
Inflammation plays a key role in the pathogenesis and progression of atherosclerosis.1 
Accordingly, several inflammatory biomarkers have been prospectively associated with all-
cause mortality2-4 and a broad set of cardiovascular outcomes including atrial fibrillation, 
stroke and myocardial infarction.5-9 
The autonomic nervous system (ANS) is strongly involved in different mechanisms of the 
cardiovascular system. Heart rate variability (HRV) has become a validated marker of the 
autonomic function.10,11 A reduced HRV is associated with an increased risk for 
cardiovascular and all-cause mortality.12,13 Interestingly, experimental studies have 
suggested direct relationships between inflammation and the ANS.14,15 Thus, autonomic 
dysfunction might be one mechanism why individuals with elevated inflammatory biomarkers 
have an increased cardiovascular risk. Up to now, some studies in rather small populations 
have evaluated the relationship between inflammation and HRV, and mainly inverse 
relationships have been described.16-19 However, information on inflammatory biomarkers 
other than high-sensitivity C-reactive protein (hs-CRP) is scarce.20 In addition, inflammatory 
biomarkers have recently been associated with heart rate (HR),21 which by itself is an 
independent risk factor for cardiovascular outcomes.22 Given the tight link between HRV and 
HR,23 it is currently unclear whether HRV contains any additional information over and above 
HR.  
In order to get a deeper understanding of these interrelationships between inflammation and 
the ANS, we assessed the relationships of 24-hour (h) HR and HRV with several 
inflammatory biomarkers in a large population based cohort of young and healthy adults from 
the general population.  
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Methods 
All inhabitants of the Principality of Liechtenstein aged between 25 to 41 years were invited 
to participate in the Genotypic and Phenotypic Determinants of Blood Pressure and other 
Cardiovascular Risk Factors (GAPP) study, a prospective population-based cohort study. 
Study design and methodology have been published previously.24 Main exclusion criteria 
were established cardiovascular disease, known renal failure, current intake of antidiabetic 
drugs, a body mass index (BMI) >35kg/m2 or any other severe illness. Overall, 2170 
participants were successfully enrolled in GAPP. For the present study we excluded 106 
participants for the following reasons: missing 24-h electrocardiogram (ECG) or recording 
time <80% of the target time (n=39), regular intake of beta blockers (n=2), missing laboratory 
values (n=10) and other missing covariates (n=55), leaving 2064 participants for the current 
analysis. The study protocol was approved by the local ethics committee and all study 
participants have signed a written informed consent.  
24-hour electrocardiogram 
Participants underwent 24-h Holter ECG monitoring using a validated three-channel device 
(Schiller AG, Baar, Switzerland). The 24-h ECG was attached by trained study nurses and 
started in the morning immediately after the study examination. Recordings with a duration of 
less than 80% of the target time (i.e. <19.2 hours) or of low quality were repeated whenever 
possible. Every 24-h ECG study was post-processed using a dedicated software to remove 
artefacts and redefine premature ventricular and atrial beats (Medilog Darwin, Schiller AG, 
Baar, Switzerland). Mean 24-h ambulatory HR was automatically calculated by the software. 
All heart beats defined as normal were used to calculate HRV. For this analysis, we used the 
standard deviation of all normal RR intervals (SDNN), total power (TP), low frequency (LF) 
and high frequency (HF) to quantify HRV. SDNN is measured in milliseconds (ms) whereas 
TP, LF and HF are measured in ms2.The low and high frequency band is between 0.04-0.15 
and 0.15-0.40Hz, respectively. LF and HF were normalized by calculating LF/(TP-VLF)*100 
and HF /(TP-VLF)*100, respectively, to receive values independent of total power (TP). 
SDNN was pre-defined as the main HRV outcome variable.  
Blood sampling 
Fasting venous blood samples were collected of every participant and immediately 
processed. Total number of leukocytes (LC), neutrophils, lymphocytes and monocytes were 
quantified using a validated method (Sysmex XE 5000, Japan). Hs-CRP, low density 
lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) were 
assayed on a Roche Cobas 6000 analyzer (Roche, Switzerland). Glycated hemoglobin A1c 
(HbA1c) was measured using high performance liquid chromatography (Bio-Rad D-10, Bio-
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Rad Laboratories AG, Switzerland). Prediabetes was defined as an HbA1c between 5.6 and 
6.4%.25 
Assessment of other study variables 
Information about personal, medical, lifestyle and nutritional factors were self-assessed using 
standardized questionnaires.24 Smoking status was classified as never, former or current 
smoking. Highest educational status achieved was divided into three categories: high school, 
college or university degree. Fruit/vegetable consumption was dichotomized into ≥5 and <5 
servings per day. Alcohol consumption was dichotomized into drinkers and non-drinkers. 
Moderate and vigorous physical activity was estimated using the International Physical 
Activity Questionnaire (IPAQ).26 Regular physical activity was defined as moderate activity 
≥150 or vigorous activity ≥75 minutes per week, respectively. Height and weight were directly 
measured in a standardized way. BMI was calculated as weight in kilograms divided by 
height in meters squared. Body fat was assessed by bioelectrical impedance analysis using 
a validated device (BIA egofit, 2010, Eggstätt, Germany). Conventional blood pressure was 
measured three times in a sitting position after five minutes of rest. The mean of the second 
and third measurement was used for the current analysis.  
Statistical analysis 
Baseline characteristics were stratified by sex. Data are presented as medians (interquartile 
ranges) for continuous variables and numbers (percentages) for dichotomous variables. 
Group comparisons were done using Wilcoxon rank sum tests or Chi-square tests as 
appropriate. Distribution of continuous variables was checked using skewness, kurtosis and 
visual inspection of the histogram.  
In order to assess the linearity of the relationships between HRV and inflammatory 
biomarkers we evaluated SDNN, HF and LF measures across quartiles of individual 
inflammatory biomarkers in separate multivariable models. P values for trend were calculated 
using quartile-specific medians. After confirming approximately linear relationships, we 
entered inflammatory biomarkers as continuous parameters in the multivariable models. Due 
to the skewed distribution, inflammatory variables were log-transformed for all analyses. To 
improve comparability across biomarkers, we calculated β-coefficients (95% confidence 
interval (CI)) per one standard deviation (SD) increase. In order to have a better 
comparability of the effect sizes all HRV variables were transformed into z-scores. The 
multivariable models were adjusted for age, sex, BMI, smoking status, educational status, 
alcohol consumption, systolic blood pressure, prediabetes, fruit and vegetable consumption, 
physical activity, LDL-C, HDL-C and body fat. To assess whether HRV has an incremental 
effect beyond HR, we additionally adjusted all models for ambulatory HR in a separate step. 
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Finally, in similar models we used 24-h HR instead of HRV as the outcome variable to 
assess its relationship with inflammatory biomarkers. A p-value <0.05 was pre-defined to 
indicate statistical significance. Statistical analyses were done using SAS 9.4 (SAS Institute 
Inc, Cary, North Carolina, USA). 
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Results 
Baseline characteristics stratified by sex are presented in Table 1. The median age of the 
population was 36.9 years and 46.7% were men. Compared to women, men had a 
significantly higher BMI (median 25.6 versus 22.5 kg/m2, p<0.0001), were more often current 
smokers (25.1 versus 19.1%, p<0.0001), had higher systolic and diastolic blood pressure 
values and a worse cholesterol profile (all p-values <0.0001). There were no significant 
differences for hs-CRP (0.9 versus 0.9 mg/l, p=0.39) and total LC count (5.3 and 5.3 G/l, 
p=0.38). Men had a significantly higher lymphocyte (1.8 versus 1.7 G/l, p=0.004) and 
monocyte count (0.5 versus 0.4 G/l, p<0.0001) and women had a higher neutrophil count 
(2.9 versus 2.8 G/l, p=0.02). The SDNN, TP and normalized LF were significantly higher in 
men than in women with (156 versus 145 ms, 4096 versus 3060 ms2 and 57 versus 51 ms2, 
respectively; all p-values <0.0001). Normalized HF was significantly higher among women 
compared to men (16 versus 13 ms2, p<0.0001). 
Relationships between heart rate variability and inflammatory biomarkers 
Results of the multivariable linear regression analyses comparing SDNN values across 
quartiles of inflammatory parameters are shown in Table 2. There were significant inverse 
and linear associations of SDNN with hs-CRP, LC, neutrophils, lymphocytes and monocytes 
after multivariable adjustment. Additional adjustment for ambulatory HR strongly attenuated 
these effect sizes, but all associations remained statistically significant (Table 2). The 
association between TP and inflammatory biomarkers was similar, except the not significant 
relationship with lymphocytes (Table S1). Normalized HF was inversely related to neutrophils 
and monocytes (Table S2). There was no relationship with hs-CRP and lymphocytes, and 
the association with total LC count was of borderline significance (p=0.08). There were 
positive linear relationships of normalized LF with total LC count and neutrophils as well as 
an inverse relationship with hs-CRP (Table S3). The relationships of both LF and HF with 
inflammatory biomarkers were strongly attenuated after the additional adjustment for 24-h 
HR and most became non-significant (Tables S2 and S3).  
Results of the relationships between HRV variables and continuous inflammatory biomarkers 
were similar to these results and are presented in Figures 1-3 and S1. After adjustment for 
24-h HR, the relationships with SDNN attenuated by 36.4% for hs-CRP, 53.9% for LC, 66.7% 
for neutrophils and 50.0% for monocytes, even though all of them remain significant. The 
attenuation effect of the correlation between TP and inflammatory biomarkers was even 
stronger, such that only the relationship with hs-CRP remained significant (Figure S1). The 
multivariable adjusted β-coefficients for normalized HF and LF are shown in Figures 2 and 3. 
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Again, all relationships were strongly attenuated after the adjustment for 24-h HR and none 
of them remained statistically significant.  
Relationships between ambulatory heart rate and inflammatory biomarkers 
A positive and linear association was found for the association of ambulatory HR with hs-
CRP, LC, neutrophils and monocytes (Table S4). Per one SD increase on the log-scale the 
multivariable adjusted β-coefficients (95%CI) were 0.68 (0.30; 1.07), p=0.0005 for hs-CRP, 
1.21 (0.83; 1.58), p<0.0001 for LC, 1.38 (1.01; 1.75), p<0.0001 for neutrophils and 0.66 
(0.28; 1.04), p=0.0007 for monocytes (Figure 4). Additional adjustment for SDNN lowered the 
effect sizes of these relationships by 74% for hs-CRP, 47% for LC, 38% for neutrophils and 
4.5% for monocytes, however with the exception of hs-CRP, all of them remained statistically 
significant. Lymphocyte count was not significantly associated with HR after multivariable 
adjustment.  
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Discussion 
In this large population-based study we found strong and independent relationships of HR 
and HRV as measured by SDNN with a large set of inflammatory biomarkers, including hs-
CRP, total LC count and several LC subpopulations. These relationships persisted after 
comprehensive multivariable adjustment but were strongly attenuated after additional 
adjustment for either ambulatory HR or HRV. Although these results suggest that HR and 
HRV carry similar information with regard to their association with inflammatory biomarkers,23 
it is important to emphasize that most relationships remained statistically significant after 
mutual adjustment, suggesting that both parameters carry some incremental information over 
each other. Finally, TP and normalized HF and LF did not provide additional information over 
and above ambulatory HR alone.  
Our findings confirm and expand prior studies showing negative associations of HRV with 
mainly hs-CRP.16-19 Importantly, our results were additionally adjusted for HR, providing 
incremental information. The consistent results across various inflammatory biomarkers 
found in our study may also indicate a broad interplay between different inflammatory 
pathways and the ANS. These data are in line with experimental studies showing direct 
relationships between of the ANS and inflammatory cells.14,15 To our knowledge this is one of 
the first studies from the general population showing the relationships of HRV and HR with 
not only hs-CRP but also total LC count and its subtypes. Thus, a direct link between HRV 
and inflammation may be one factor that explains the increased cardiovascular risk 
previously shown for both entities.2,12  
Inflammation is based on complex processes and various pathways are involved. Our 
findings showed that several inflammatory pathways seem to be involved in the relationship 
with HRV. Potential underlying mechanisms for these relationships are multifaceted. 
Norepinephrine, as the main sympathetic neurotransmitter, has been negatively associated 
with HRV and positively related to inflammatory parameters.17 Experimental studies have 
shown expression of adrenoceptors on immune cells, suggesting a direct influence of the 
immune system by adrenoceptor agonists.27-29 Additionally, other studies showed a reduced 
inflammatory reaction as a consequence of medical sympathectomy.30,31 Vagal activity 
seems to have an anti-inflammatory effect via a cholinergic pathway, which results in a 
down-regulation of pro-inflammatory cytokines.14  
Some of the described mechanisms partly explain and support our findings. HF is mainly 
modulated by parasympathetic activity.10,32 An inverse relationship of HF with neutrophils and 
monocytes was found, assuming either an anti-inflammatory effect of vagal activity for those 
immune cells or an increased vagal activity as a consequence of low neutrophil and 
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monocyte cell counts. In contrast, lymphocytes were positively related to HF. This finding 
could be supported by the results of a previous study showing a protective effect of 
lymphocytes and an adverse effect for neutrophils for the occurrence of cardiovascular 
events.33,34 Others have showed that inflammation could increase lymphocyte apoptosis, 
which may contribute to unfavorable outcomes.35 SDNN was negatively associated with all 
inflammatory biomarkers, although the relationship with the lymphocyte cell count was 
weakest and reached only borderline significance. The association of lymphocyte cell count 
with different HRV variables should further be investigated to understand the underlying 
mechanisms of the relationship between lymphocytes and autonomic function.  
Based on previous studies, resting and 24-h HR are known to be positively associated with 
hs-CRP, fibrinogen and interleukin, which is in line with our findings.17-19,21 Additionally, our 
data showed a positive association with total LC count, neutrophils and monocytes, but 
similar to HRV, no significant relationship with lymphocytes. Physical activity and other 
healthy lifestyle habits reduce HR36 and improve autonomic function, which may in 
consequence lower inflammatory biomarker levels. Others suggest that the protective effect 
of physical activity on inflammation is mediated by autonomic function.37 This cross-sectional 
study cannot prove the above mentioned pathways, but nevertheless highlights the need for 
future studies to better understand the relationship between inflammation and the ANS. 
Strengths and Limitations 
Major strengths of the present study are the population-based study design, the well-
characterized study population, the availability of 24-h ECG data to quantify HRV and the 
inclusion of young and healthy participants with a relatively short exposure history to 
environmental factors. However there are several potential limitations, which should be taken 
into account for the interpretation of our results. First, this is a cross-sectional analysis such 
that causality of the relationship between HRV and inflammatory biomarkers cannot be 
addressed. Second, we enrolled mainly Caucasians in our study and the generalizability of 
our results to other populations is uncertain. Third, as in any observational study, residual 
confounding could be an issue despite our comprehensive multivariable adjustment. Fourth, 
it is unclear if variables, such as body fat mass or BMI are confounders or mediators of the 
observed relationships. If some mediators should have been included in our models, we 
would expect that the true relationships between inflammation, HR and HRV would be 
somewhat stronger.  
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Conclusion 
In this large population of young and healthy adults from the general population, we found 
strong and independent relationships of HR and HRV with a broad set of inflammatory 
biomarkers. Relationships between SDNN and inflammatory biomarkers were weakened but 
remained significant after additional adjustment for ambulatory HR, suggesting incremental 
information of HRV over HR. Thus, our findings suggest important interrelationships between 
inflammatory pathways and the ANS.  
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Figure legend 
Figure 1 Relationship between SDNN and inflammatory biomarkers 
 Data are presented as β-coefficients (95% confidence intervals) per 1 
standard deviation increase. SDNN = standard deviation of all normal RR 
intervals: Hs-CRP = high-sensitivity C-reactive protein. Model 1 was adjusted 
for age, sex. Model 2 was additionally adjusted for body mass index, smoking 
status, educational status, alcohol consumption, fruit and vegetable 
consumption, systolic blood pressure, prediabetes, physical activity, low- and 
high density lipoprotein cholesterol and body fat. Model 3 was additionally 
adjusted for 24-hour heart rate. n = 2096. 
Figure 2 Relationship between normalized HF and inflammatory biomarkers 
Data are presented as β-coefficients (95% confidence intervals) per 1 
standard deviation increase. HF = high frequency; Hs-CRP = high-sensitivity 
C-reactive protein. Model 1 was adjusted for age, sex. Model 2 was 
additionally adjusted for body mass index, smoking status, educational status, 
alcohol consumption, fruit and vegetable consumption, systolic blood 
pressure, prediabetes, physical activity, low- and high density lipoprotein 
cholesterol and body fat. Model 3 was additionally adjusted for 24-hour heart 
rate. n = 2096. 
Figure 3 Relationship between normalized LF and inflammatory biomarkers 
Data are presented as β-coefficients (95% confidence intervals) per 1 
standard deviation increase. LF = low frequency; Hs-CRP = high-sensitivity C-
reactive protein. Model 1 was adjusted for age, sex. Model 2 was additionally 
adjusted for body mass index, smoking status, educational status, alcohol 
consumption, fruit and vegetable consumption, systolic blood pressure, 
prediabetes, physical activity, low- and high density lipoprotein cholesterol and 
body fat. Model 3 was additionally adjusted for 24-hour heart rate. n = 2096. 
Figure 4 Relationship between ambulatory heart rate and inflammatory biomarkers 
 Data are presented as β-coefficients (95% confidence intervals) per 1 
standard deviation increase. Hs-CRP = high-sensitivity C-reactive protein. 
Model 1 was adjusted for age, sex. Model 2 was additionally adjusted for body 
mass index, smoking status, educational status, alcohol consumption, fruit and 
vegetable consumption, systolic blood pressure, prediabetes, physical activity, 
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low- and high density lipoprotein cholesterol and body fat. Model 3 was 
additionally adjusted for the standard deviation of all normal RR intervals. 
SDNN = standard deviation of all normal RR intervals; n = 2096. 
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Table 1 Baseline Characteristics stratified by sex 
n=2064 
Men 
n=979 (46.7%) 
Women 
n=1117 (53.3%) 
p-value* 
Age, years 36.9 (31.6; 40.5) 36.7 (30.9; 40.1) 0.19 
BMI, kg/m2 25.6 (23.6; 27.9) 22.5 (20.6; 25.2) <0.0001 
Smoking, %   0.0003 
Current 246 (25.1) 213 (19.1)  
Former 240 (24.5) 250 (22.4)  
Never 493 (50.4) 654 (58.6)  
Systolic BP, mmHg 127 (121; 135) 113 (107; 120) <0.0001 
Diastolic BP, mmHg 82.0 (77.5; 87.5) 74.5 (69.5; 79.5) <0.0001 
LDL-C, mmol/l 3.2 (2.7; 3.8) 2.6 (2.2; 3.1) <0.0001 
HDL-C, mmol/l 1.3 (1.1; 1.5) 1.7 (1.5; 1.9) <0.0001 
HbA1c, % 5.4 (5.2; 5.7) 5.4 (5.2; 5.6) 0.001 
Education, %   <0.0001 
Basic 64 (6.5) 108 (9.7)  
Middle 489 (50.0) 651 (58.3)  
University 426 (43.5) 358 (32.0)  
Hs-CRP, mg/l 0.9 (0.5; 1.8) 0.9 (0.5; 2.1) 0.39 
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Leukocytes, G/l 5.3 (4.6; 6.2) 5.3 (4.5; 6.1) 0.38 
Neutrophils 2.8 (2.3; 3.4) 2.9 (2.3; 3.6) 0.02 
Lymphocytes 1.8 (1.5; 2.1) 1.7 (1.4; 2.1) 0.004 
Monocytes 0.5 (0.4; 0.6) 0.4 (0.3; 0.5) <0.0001 
SDNN, ms 156 (132; 185) 145 (121; 168) <0.0001 
Total power, ms2 4096 (2846; 5901) 3060 (2184; 4241) <0.0001 
LF normalized, ms2 57 (53; 62) 51 (46; 56) <0.0001 
HF normalized, ms2 13 (10; 17) 16 (12; 21) <0.0001 
Heart Rate 24-h, bpm 72.2 (66.6; 78.8) 76.9 (71.9; 82.2) <0.0001 
Data are median (interquartile range) or numbers (percentages). BMI = body mass index; BP = blood pressure; LDL-C = low-density lipoprotein cholesterol; HDL-
C = high-density lipoprotein cholesterol; HbA1c = glycated hemoglobin A1c; hs-CRP = high-sensitivity c-reactive protein; SDNN = standard deviation of all normal 
RR intervals; LF = low frequency; HF = high frequency. 
* P-values are based on Wilcoxon rank sum tests or chi-square tests, as appropriate. 
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Table 2 SDNN across quartiles of inflammatory biomarkers 
Data are β-coefficients (95% confidence interval). Model 1 adjusted for age, sex, body mass index, smoking status, educational status, alcohol consumption, 
systolic blood pressure, prediabetes, diet, physical activity, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, body fat; Model 2 additionally 
adjusted for ambulatory heart rate. LC = Leukocytes, Hs-CRP = high-sensitivity C-reactive protein.  
n=2064 Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value 
 high-sensitivity c-reactive protein  
Hs-CRP, mg/l <0.50 0.50-0.90 0.91-1.83 >1.83  
Age-sex adj. Ref. -0.12 (-0.24; -0.008) -0.18 (-0.31; -0.06) -0.46 (-0.58; -0.34) <0.0001 
Model 1 Ref. -0.05 (-0.17; 0.06) -0.05 (-0.17; 0.08) -0.26 (-0.39; 0.08) <0.0001 
Model 2 Ref. -0.03 (-0.13; 0.07) -0.07 (-0.18; 0.04) -0.17 (-0.28; -0.06) 0.0008 
   Leukocytes   
LC, G/l <4.6 4.6-5.3 5.4-6.1 >6.1  
Age-sex adj. Ref. -0.20 (-0.32; -0.09) -0.29 (-0.40; -0.17) -0.50 (-0.62; -0.38) <0.0001 
Model 1 Ref. -0.14 (-0.25; -0.02) -0.17 (-0.29; -0.06) -0.35 (-0.47; -0.22) <0.0001 
Model 2 Ref. -0.08 (-0.18; 0.02) -0.08 (-0.19; 0.02) -0.19 (-0.30; -0.09) 0.0004 
   Neutrophils   
Neutrophils, G/l <2.4 2.4-2.8 2.9-3.5 >3.5  
Age-sex adj. Ref. -0.19 (-0.31; -0.07) -0.24 (-0.35; -0.12) -0.47 (-0.58; -0.35) <0.0001 
Model 1 Ref. -0.13 (-0.24; -0.02) -0.13 (-0.24; -0.02) -0.32 (-0.44; -0.20) <0.0001 
Model 2 Ref. -0.07 (-0.17; 0.03) -0.05 (-0.15; 0.05) -0.13 (-0.23; -0.03) 0.02 
   Lymphocytes   
Lymphocytes, G/l <1.5 1.5-1.7 1.8-2.1 >2.1  
Age-sex adj. Ref. -0.10 (-0.22; 0.02) -0.14 (-0.26; -0.02) -0.24 (-0.37; -0.12) 0.0001 
Model 1 Ref. -0.07 (-0.18; 0.05) -0.07 (-0.19; 0.04) -0.12 (-0.25; -0.00) 0.06 
Model 2 Ref. -0.12 (-0.22; -0.02) -0.14 (-0.24; -0.04) -0.13 (-0.24; -0.03) 0.03 
   Monocytes   
Monocytes, G/l <0.4 0.4-0.4 0.5-0.5 >0.5  
Age-sex adj. Ref. -0.21 (-0.33; -0.09) -0.20 (-0.33; -0.08) -0.33 (-0.46; -0.21) <0.0001 
Model 1 Ref. -0.15 (-0.26; -0.03) -0.13 (-0.25; -0.01) -0.21 (-0.34; -0.09) 0.003 
Model 2 Ref. -0.07 (-0.17; 0.03) -0.07 (-0.02; 0.03) -0.11 (-0.22; -0.006) 0.05 
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Figure legend 
Figure S1 Relationship between total power and inflammatory biomarkers 
Data are presented as β-coefficients (95% confidence intervals) per 1 standard deviation 
increase. Hs-CRP = high-sensitivity C-reactive protein. Model 1 was adjusted for age, sex. 
Model 2 was additionally adjusted for body mass index, smoking status, educational status, 
alcohol consumption, fruit and vegetable consumption, systolic blood pressure, prediabetes, 
physical activity, low- and high density lipoprotein cholesterol and body fat. Model 3 was 
additionally adjusted for 24-hour heart rate. n = 2096.  
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Table S1 Total power across quartiles of inflammatory markers 
Data are β-coefficients (95% confidence interval). Model 1 adjusted for age, sex, body mass index, smoking status, educational status, alcohol consumption, 
systolic blood pressure, prediabetes, diet, physical activity, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, body fat; Model 2 additionally 
adjusted for ambulatory heart rate. LC = Leukocytes, Hs-CRP = high-sensitivity C-reactive protein 
  
n=2064 Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value 
 high-sensitivity c-reactive protein  
Hs-CRP, mg/l <0.50 0.50-0.90 0.91-1.83 >1.83  
Age-sex adj. Ref. -0.14 (-0.25; -0.02) -0.12 (-0.24; 0.00) -0.44 (-0.55; -0.32) <0.0001 
Model 1 Ref. -0.09 (-0.20; 0.02) -0.01 (-0.14; 0.11) -0.27 (-0.39; -0.15) <0.0001 
Model 2 Ref. -0.06 (-0.14; 0.03) -0.04 (-0.13; 0.06) -0.15 (-0.25; -0.06) 0.001 
   Leukocytes   
LC, G/l <4.6 4.6-5.3 5.4-6.1 >6.1  
Age-sex adj. Ref. -0.12 (-0.23;-0.01) -0.24 (-0.36; -0.12) -0.48 (-0.59; -0.36) <0.0001 
Model 1 Ref. -0.05 (-0.16; 0.06) -0.11 (-0.22; 0.008) -0.26 (-0.37; -0.14) <0.0001 
Model 2 Ref. 0.02 (-0.06; 0.11) 0.003 (-0.09; 0.09) -0.07 (-0.16; 0.02) 0.07 
   Neutrophils   
Neutrophils, G/l <2.4 2.4-2.8 2.9-3.5 >3.5  
Age-sex adj. Ref. -0.11 (-0.22; 0.007) -0.18 (-0.30; -0.007) -0.49 (-0.60; -0.38) <0.0001 
Model 1 Ref. -0.05 (-0.16; 0.06) -0.08 (-0.19; 0.03) -0.31 (-0.42; -0.19) <0.0001 
Model 2 Ref. 0.02 (-0.06; 0.11) 0.02 (-0.07; 0.10) -0.08 (-0.17; 0.01) 0.05 
   Lymphocytes   
Lymphocytes, G/l <1.5 1.5-1.7 1.8-2.1 >2.1  
Age-sex adj. Ref. 0.02 (-0.10; 0.14) -0.07 (-0.18; 0.05) -0.14 (-0.26; -0.02) 0.009 
Model 1 Ref. 0.07 (-0.04; 0.18) 0.04 (-0.08; 0.15) 0.06 (-0.06; 0.18) 0.50 
Model 2 Ref. 0.002 (-0.09; 0.09) -0.04 (-0.13; 0.04) 0.05 (-0.05; 0.14) 0.41 
   Monocytes   
Monocytes, G/l <0.4 0.4-0.4 0.5-0.5 >0.5  
Age-sex adj. Ref. -0.14 (-0.26; -0.02) -0.16 (-0.28; -0.04) -0.32 (-0.44; -0.20) <0.0001 
Model 1 Ref. -0.08 (-0.19; 0.03) -0.07 (-0.18; 0.05) -0.14 (-0.26; -0.01) 0.05 
Model 2 Ref. 0.02 (-0.07; 0.10) -0.00 (-0.09; 0.09) -0.02 (-0.11; 0.08) 0.61 
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Table S2 Normalized high frequency across quartiles of inflammatory markers 
Data are β-coefficients (95% confidence interval). Model 1 adjusted for age, sex, body mass index, smoking status, educational status, alcohol consumption, 
systolic blood pressure, prediabetes, diet, physical activity, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, body fat; Model 2 additionally 
adjusted for ambulatory heart rate. LC = Leukocytes, Hs-CRP = high-sensitivity C-reactive protein.  
n=2064 Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value 
 high-sensitivity c-reactive protein  
Hs-CRP, mg/l <0.50 0.50-0.90 0.91-1.83 >1.83  
Age-sex adj. Ref. 0.01 (-0.10; 0.12) 0.09 (-0.03; 0.20) -0.00 (-0.12; 0.11) 0.84 
Model 1 Ref. 0.01 (-0.10; 0.12) 0.09 (-0.03; 0.21) 0.05 (-0.12; 0.13) 0.90 
Model 2 Ref. 0.03 (-0.08; 0.13) 0.08 (-0.04; 0.19) 0.07 (-0.05; 0.18) 0.31 
   Leukocytes   
LC, G/l <4.6 4.6-5.3 5.4-6.1 >6.1  
Age-sex adj. Ref. -0.06 (-0.17; 0.05) -0.07 (-0.18; 0.05) -0.12 (-0.23; -0.07) 0.05 
Model 1 Ref. -0.07 (-0.18; 0.05) -0.07 (-0.18; 0.05) -0.12 (-0.23; 0.003) 0.08 
Model 2 Ref. -0.03 (-0.13; 0.08) -0.008 (-0.12; 0.10) -0.01 (-0.13; 0.10) 0.94 
   Neutrophils   
Neutrophils, G/l <2.4 2.4-2.8 2.9-3.5 >3.5  
Age-sex adj. Ref. -0.06 (-0.17; 0.05) -0.08 (-0.19; 0.03) -0.15 (-0.26; -0.04) 0.007 
Model 1 Ref. -0.06 (-0.17; 0.05) -0.08 (-0.20; 0.03) -0.15 (-0.27; -0.04) 0.01 
Model 2 Ref. -0.02 (-0.13; 0.08) -0.03 (-0.14; 0.07) -0.03 (-0.06; 0.08) 0.64 
   Lymphocytes   
Lymphocytes, G/l <1.5 1.5-1.7 1.8-2.1 >2.1  
Age-sex adj. Ref. 0.04 (-0.07; 0.16) 0.04 (-0.07; 0.15) 0.04 (-0.08; 0.16) 0.55 
Model 1 Ref. 0.06 (-0.05; 0.17) 0.06 (-0.05; 0.18) 0.07 (-0.05; 0.19)) 0.29 
Model 2 Ref. 0.02 (-0.08; 0.13) 0.02 (-0.08; 0.13) 0.07 (-0.05; 0.18) 0.27 
   Monocytes   
Monocytes, G/l <0.4 0.4-0.4 0.5-0.5 >0.5  
Age-sex adj. Ref. -0.12 (-0.23; -0.005) -0.09 (-0.21; 0.02) -0.15 (-0.27; -0.03) 0.03 
Model 1 Ref. -0.12 (-0.23; -0.009) -0.09 (-0.21; 0.03) -0.15 (-0.27; -0.03) 0.04 
Model 2 Ref. -0.07 (-0.18; 0.04) -0.05 (-0.16; 0.06) -0.09 (-0.20; 0.03) 0.21 
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Table S3 Normalized low frequency across quartiles of inflammatory markers 
Data are β-coefficients (95% confidence interval). Model 1 adjusted for age, sex, body mass index, smoking status, educational status, alcohol consumption, 
systolic blood pressure, prediabetes, diet, physical activity, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, body fat; Model 2 additionally 
adjusted for ambulatory heart rate. LC = Leukocytes, Hs-CRP = high-sensitivity C-reactive protein.  
n=2064 Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value 
 high-sensitivity c-reactive protein  
Hs-CRP, mg/l <0.50 0.50-0.90 0.91-1.83 >1.83  
Age-sex adj. Ref. 0.009 (-0.11; 0.12) -0.09 (-0.21; 0.04) -0.13 (-0.25; -0.01) 0.008 
Model 1 Ref. -0.004 (-0.12; 0.11) -0.10 (-0.23; 0.03) -0.14 (-0.27; -0.01) 0.01 
Model 2 Ref. -0.02 (-0.13; 0.10) -0.09 (-0.21; 0.03) -0.19 (-0.31; -0.06) 0.0008 
   Leukocytes   
LC, G/l <4.6 4.6-5.3 5.4-6.1 >6.1  
Age-sex adj. Ref. 0.11 (-0.002; 0.23) 0.07 (-0.05; 0.18) 0.11 (-0.003; 0.23) 0.14 
Model 1 Ref. 0.12 (0.01; 0.24) 0.09 (-0.03; 0.20) 0.18 (0.06; 0.30) 0.01 
Model 2 Ref. 0.10 (-0.01; 0.21) 0.04 (-0.07; 0.16) 0.10 (-0.01; 0.22) 0.18 
   Neutrophils   
Neutrophils, G/l <2.4 2.4-2.8 2.9-3.5 >3.5  
Age-sex adj. Ref. 0.11 (-0.01; 0.22) 0.12 (0.006; 0.23) 0.12 (0.008; 0.24) 0.06 
Model 1 Ref. 0.11 (-0.001; 0.23) 0.13 (0.01; 0.24) 0.17 (0.05; 0.29) 0.008 
Model 2 Ref. 0.09 (-0.03; 0.20) 0.09 (-0.02; 0.20) 0.08 (-0.04; 0.20) 0.24 
   Lymphocytes   
Lymphocytes, G/l <1.5 1.5-1.7 1.8-2.1 >2.1  
Age-sex adj. Ref. -0.02 (-0.13; 0.10) -0.02 (-0.13; 0.10) -0.05 (-0.17; 0.07) 0.41 
Model 1 Ref. 0.00 (-0.12; 0.12) -0.01 (-0.13; 0.10) -0.30 (-0.10; 0.13) 0.61 
Model 2 Ref. 0.03 (-0.09; 0.14) 0.02 (-0.09; 0.13) -0.02 (-0.15; 0.10) 0.61 
   Monocytes   
Monocytes, G/l <0.4 0.4-0.4 0.5-0.5 >0.5  
Age-sex adj. Ref. -0.01 (-0.13 ; 0.11) 0.01 (-0.11; 0.13) 0.02 (-0.10; 0.14) 0.66 
Model 1 Ref. 0.002 (-0.11; 0.12) 0.04 (-0.09; 0.16) 0.07 (-0.06; 0.16) 0.23 
Model 2 Ref. -0.04 (-0.15; 0.08) 0.01 (-0.11; 0.13) 0.02 (-0.10; 0.14) 0.55 
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Table S4  Ambulatory heart rate across quartiles of inflammatory markers 
Data are β-coefficients (95% confidence interval). Model 1 adjusted age, sex, body mass index, smoking status, educational status, alcohol consumption, systolic 
blood pressure, prediabetes, diet, physical activity, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, body fat; Model 2 additionally adjusted 
for the standard deviation of all normal RR intervals. LC = Leukocytes, Hs-CRP = high-sensitivity C-reactive protein.  
n=2064 Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value 
 high-sensitivity c-reactive protein  
Hs-CRP, mg/l <0.50 0.50-0.90 0.91-1.83 >1.83  
Age-sex adj. Ref. 0.71 (-0.36; 1.78) 0.51 (-0.62; 1.65) 3.44 (2.34; 4.55) <0.0001 
Model 1 Ref. 0.45 (-0.55; 1.45) -0.36 (-1.46; 0.74) 1.62 (0.81; 2.72) 0.002 
Model 2 Ref. 0.21 (-0.66; 1.07) -0.57 (-1.52; 0.37) 0.44 (-0.52; 1.40) 0.31 
   Leukocytes   
LC, G/l <4.6 4.6-5.3 5.4-6.1 >6.1  
Age-sex adj. Ref. 1.53 (0.48; 2.59) 2.58 (1.49; 3.67) 4.33 (3.26; 5.40) <0.0001 
Model 1 Ref. 0.98 (-0.01; 1.97) 1.56 (0.52; 2.59) 2.69 (1.64; 3.74) <0.0001 
Model 2 Ref. 0.38 (-0.47; 1.23) 0.78 (-0.11; 1.68) 1.15 (0.23; 2.06) 0.01 
   Neutrophils   
Neutrophils, G/l <2.4 2.4-2.8 2.9-3.5 >3.5  
Age-sex adj. Ref. 1.40 (0.34; 2.46) 2.41 (1.36; 3.46) 5.09 (4.04; 6.14) <0.0001 
Model 1 Ref. 0.99 (-0.00; 1.98) 1.33 (0.34; 2.32) 3.26 (2.25; 4.28) <0.0001 
Model 2 Ref. 0.42 (-0.44; 1.27) 0.76 (-0.10; 1.61) 1.86 (0.97; 2.74) <0.0001 
   Lymphocytes   
Lymphocytes, G/l <1.5 1.5-1.7 1.8-2.1 >2.1  
Age-sex adj. Ref. -0.91 (-2.01; 0.19) -0.88 (-1.95; 0.18) 1.07 (-0.04; 2.18) 0.003 
Model 1 Ref. -0.95 (-1.97; 0.06) -1.13 (-2.14; -0.12) -0.16 (-1.24; 0.92) 0.95 
Model 2 Ref. -1.25 (-2.13; -0.38) -1.46 (-2.33; -0.59) -0.72 (-1.65; 0.21) 0.23 
   Monocytes   
Monocytes, G/l <0.4 0.4-0.4 0.5-0.5 >0.5  
Age-sex adj. Ref. 1.23 (0.04; 2.21) 0.42 (-0.71; 1.54) 1.49 (0.37; 2.62) <0.0001 
Model 1 Ref. 1.39 (0.39; 2.40) 0.93 (-0.13; 1.94) 1.72 (0.63; 2.81) 0.01 
Model 2 Ref. 0.73 (-0.13; 1.60) 0.36 (-0.55; 1.27) 0.77 (-0.17; 1.71) 0.24 
6.MANUSCRIPT 3 – HRV, HR and inflammation 
 
89 
 
-0.18
-0.19 -0.19
-0.06
-0.13
-0.12
-0.11
-0.12
0.02
-0.06
-0.07
-0.02
-0.02
0.01
-0.01
-0.25
-0.20
-0.15
-0.10
-0.05
0.00
0.05
0.10
β
-
c
o
e
f
f
i
c
i
e
n
t
 
(
9
5
%
 
C
I
)
age-sex adjusted
multivariable adjusted model
multivariable adjusted model + 24HR
Figure S1 Relationship between total power and inflammatory biomarkers 
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7.SUMMARY OF THE MAIN FINDINGS 
The results of this project will be summarized in this chapter and illustrated in Figure 6.  
7.1 Healthy lifestyle and heart rate variability 
The validated lifestyle-score is based on seven cardiovascular health metrics and lifestyle 
factors, such as smoking, BMI, physical activity, diet, blood pressure, cholesterol and HbA1c. 
The score is scaled from 0-7, where 0=very unhealthy and 7=very healthy. Around 5% of 
2070 study participants had a very unhealthy score of 0 or 1 and 11% had a very healthy 
score of 6 or 7. Overall, a healthy lifestyle was more often adopted by women compared to 
men with a prevalence of 18% and 3%, respectively. There was a strong positive association 
of the lifestyle-score with HRV and an inverse relationship with ambulatory and resting HR. 
The relationship between HRV and the lifestyle-score was strongly attenuated after 
additional adjustment for either resting or ambulatory HR, however most relationships 
remained statistically significant. Never smoking cigarettes, regular physical activity and 
having a normal BMI were the strongest individual and independent predictors of SDNN. 
7.2 Heart rate variability and sleep-related breathing disorders 
Overall, 1255 participants without known OSA were included in this analysis. Among this 
young and relatively healthy population, 9.6% had an AHI defined sleep-related breathing 
disorder, where men were significantly more often affected compared to women (18% versus 
3%). SDNN and TP were linear inversely associated with AHI and ODI categories. Moreover, 
normalized LF was positively associated across ODI categories. SDNN and TP were 
significantly associated with sleep-related breathing disorder, using either the AHI or ODI 
based definition. Additional adjustment for resting HR has weakened these relationships in 
order that only associations with ODI remained significant. The adjustment for ambulatory 
HR has even stronger attenuated these relationships and virtually all of them lost level of 
significance. Resting and ambulatory HR by itself was positively associated with AHI and 
ODI categories and sleep-related breathing disorders. However, only the relationships of 
ambulatory HR with AHI and ODI were associated independently of HRV. 
7.3 Heart rate variability, heart rate and inflammation 
We found a strong, linear and inverse relationship of SDNN with hs-CRP, LC, neutrophils, 
lymphocytes and monocytes, even after comprehensive multivariable adjustment. These 
results were strongly attenuated after additional adjustment for ambulatory HR, suggesting 
only little incremental information of HRV over and above HR. Normalized HF, mainly 
modulated by parasympathetic activity was inversely associated with neutrophils and 
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monocytes, however positively related to lymphocytes. In contrast, normalized LF, modulated 
by sympathetic and parasympathetic activity, was positively associated with neutrophils. 
There was a strong positive association between ambulatory HR and all available 
inflammatory biomarkers with the exception of lymphocytes. 
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Figure 6 Simplified diagram of the study results. 
Solid lines are showing new relationships; dashed lines are corresponding to associations based on current literature. 
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8.DISCUSSION  
In the following paragraph our findings will be compared with the existing literature and 
potential underlying mechanisms will be described. Additionally, methodological and 
technical aspects will be critically elucidated, to avoid misunderstandings when interpreting 
the results. Finally, the relevance of this project and potential implications for further research 
will be outlined to even improve and deepen the knowledge in this field of research.  
 
8.1 Subject-specific discussion 
8.1.1 Heart rate variability and its meaning 
It is well known that the ANS plays an important role in several processes of the 
cardiovascular system.41 To find a way to measure the function of the ANS was therefore 
important to further investigate the role of the ANS in the development diseases. By 
performing intraneural recordings, activity of the ANS can be measured. Due to the complex 
intervention to obtain intraneural recordings, this approach is not useful in cohort studies. 
The HRV, as a relative easily measurable variable, is a suitable tool to estimate the function 
of the ANS. As elucidated in the background (chapter 1), HRV is based on the variation of 
the HR, which is determined by autonomic inputs to the sinus node. The HRV is a measure 
of the modulation of the HR and does not reflect autonomic tone.43-45 Therefore, it is very 
important to distinguish between the terms “autonomic modulation” and “autonomic tone” 
(activity), which are often used interchangeably in the existing literature.44  
An experimental study 30 years ago showed that the HF component of the HRV is mainly 
modulated by the parasympathetic activity. The parasympathetic induced modulation causes 
short cycle lengths (0.15-0.40 Hz) of the normal sinus rhythm. However, to interpret HF as a 
general measure of the parasympathetic tone is not fully correct and one has to be cautious 
when interpreting such results. Increased HF levels rather indicates an increased modulation 
of parasympathetic activity.44 The LF component of the HRV is modulated by sympathetic 
and parasympathetic activity and the interpretation of this parameter is controversially 
discussed. Absolute LF and HF values are based on the total variance of HRV. Since total 
variance is depending on different factors (e.g. recording length of the ECG), changes in total 
variance influence both components (LF and HF) in the same direction.43,84 Based on this 
phenomenon, it is crucial to normalize LF and HF to assess these components 
independently of the total variance.  
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In contrast to the frequency-domain variables, SDNN is a measure of the total variance and 
the circadian rhythm and cannot be assigned to a physiologic correlate, such as sympathetic 
or parasympathetic activity.45 SDNN is very simple to calculate and commonly used in HRV 
analysis, even though the interpretation of the SDNN is limited. Moreover, SDNN has 
showed to be a strong predictor for cardiovascular outcomes and mortality over the last 30 
years, which increases the importance of this variable.49,85  
It should be highlighted that further research is needed in this area to better understand the 
physiologic correlate of the single HRV variables. This would allow a more accurate 
interpretation of the results. 
 
8.1.2 Associations of HRV with lifestyle factors, sleep-related breathing disorders 
and inflammation  
It is known that lifestyle-factors, cardiovascular health metrics, sleep-related breathing 
disorders and inflammation are associated with an increased risk of cardiovascular outcomes 
and mortality. However, the role of the ANS in these associations is unclear. Based on this 
evidence it was aimed to determine the association of lifestyle and lifestyle-related factors 
with the autonomic function, measured using HRV. As summarized in chapter 7, HRV was 
associated with lifestyle and cardiovascular health metrics, sleep-related breathing disorders 
and inflammatory biomarkers. Due to several possible influencing factors, the context of 
these associations is complex. To thoroughly think about possible confounders, mediators or 
potential modifying factors of each association is an enormously important process. The risk 
of residual confounding or over-adjustment exists and should to be minimized as best as 
possible. To investigate our research questions in a young and healthy population without 
established cardiovascular disease, reduces the risk of confounding factors. 
 
Heart rate variability, lifestyle factors, cardiovascular health metrics and potential underlying 
mechanisms 
HRV was found to be linearly associated with increasing lifestyle-score, suggesting an 
incremental effect of combined lifestyle factors on the autonomic function. We are not aware 
of other large population-based studies showing this association. We have checked the 
relationship for different potential effect modifier, such as sex or educational status. The 
results were consistent across all strata. The underlying mechanisms that connect an 
unhealthy lifestyle with the ANS are multifaceted and not completely understood. According 
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to our study, overweight, physical inactivity and smoking were the main drivers of this 
association.  
Recent studies showed that smoking cigarettes can influence the ANS.86-88 Fine particulate 
matter and nicotine may stimulate different cascades, leading to sympathetic overactivity. 
Impaired baroreceptor sensitivity with a deficient negative feedback-loop plays an important 
role in this context.87,88 Moreover, a direct effect of nicotine on the central nervous system via 
nicotinic receptors is discussed.86 Additionally, lung oxidative stress and inflammation, mainly 
triggered by fine particulate matter, might increase sympathetic nerve activity due to 
stimulation of receptors on lung C-fibers.86 These triggered pathways may lead to the strong 
association between smoking cigarettes and the autonomic function.  
Regarding the association of physical activity and HRV, our findings are in line with prior 
published studies, showing positive associations of HRV with physical activity.58,60-62 Among 
middle-aged women randomized to different physical activity intervention programs over 6 
months, time- and frequency domain HRV variables were significantly higher compared to 
controls without intervention. Even moderate activity was sufficient to significantly improve 
HRV.62 One reason for the favorable effect of regular physical activity on the autonomic 
function may include beneficial functional and structural modifications of the cardiovascular 
system.89 Moreover, regular physical activity has shown to have the ability to lower 
inflammation.37,38 Since there is an interrelationship between inflammation and the ANS, the 
anti-inflammatory effect of physical activity might also contribute to a more balanced ANS in 
physically active individuals.  
Further, BMI previously showed to be strongly associated with HRV. Based on data of the 
SAPALDIA study, the authors presented markedly lower HRV levels among overweight and 
obese participants compared to normal weight individuals.60 However, obese but physically 
active participants had HRV values comparable to normal weight individuals. Losing weight 
based on a 12-week dietary program resulted in significantly higher HRV levels.90 Thus, body 
fat mass, mainly visceral fat, could be involved in the relationship between BMI and HRV. In 
recent studies, inflammation has shown to be associated with BMI and WHR36 as well as the 
ANS,91,92 which supports the assumption that inflammation might play an important role in the 
association of BMI and HRV. Since inflammation is highly influenced by lifestyle factors and 
cardiovascular health metrics, it may play an important role in the relationship with the 
autonomic function.  
Based on the linear relationship between the health metric score and the HRV, the different 
underlying pathways seem to add up their negative influence on the ANS.  
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Heart rate variability, sleep-related breathing disorders and potential underlying mechanisms 
Among our young population without known OSA, AHI and ODI were significantly associated 
with HRV, mainly SDNN and TP. Additionally, ODI was positively associated with normalized 
LF, which is modulated by sympathetic and parasympathetic nerve activity. Normalized HF 
values were significantly higher among individuals with an AHI<5 compared to others. 
However, normalized HF was not associated with AHI and ODI after a comprehensive 
adjustment. Based on these findings, increased sympathetic activity, but not decreased 
parasympathetic activity might be assumed in this young and mainly asymptomatic 
population. 
Population-based studies investigating the association of sleep-related breathing disorders 
with HRV are scarce. Few small studies have shown a markedly worse HRV profile among 
OSA patients compared to healthy controls.67-69 This was confirmed in our study with 
participants without clinically overt OSA. The positive association of AHI and ODI with HRV is 
supported by another study that assessed autonomic activity using direct intraneural 
recordings. Compared to healthy controls, patients with overt OSA had markedly higher 
sympathetic nerve activity during the entire day.93 Thus, repeated apneas among individuals 
with overt OSA followed by arousals are strongly associated with an increased sympathetic 
activity, potentially explaining the strong relationship between OSA and the occurrence of 
cardiovascular events. In contrast to our study, the current evidence in this field of research 
is mainly based on patients with a severe OSA, which could affect the comparability of the 
studies. 
Patients with a manifest OSA have repetitive interruptions of the ventilation due to collapsing 
airways over at least 10 seconds.16 Such interruptions might provoke stress reactions and 
activate arterial chemoreceptors, which in turn increase sympathetic activity via the 
brainstem (medulla oblongata).94 These changes in the ANS activity might be reflected by 
the autonomic modulation and therefore the HRV. According to our data, differences in HRV 
profile are an early phenomenon in the pathophysiology of sleep-related breathing disorders 
and do exist already among healthy participants with early, subclinical stages of sleep-
related breathing disorders. Whether there are long-term effects in individuals with early 
stages of breathing disorders during sleep is currently not known. However, it is plausible 
that modifications in direction of an autonomic dysbalance among individuals with early 
stages of sleep-related breathing disorders could have serious consequences later on. 
Future studies should explore ways on how to best approach individuals with subclinical 
forms of sleep-related breathing disorders.  
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Heart rate variability, inflammatory biomarkers and potential underlying mechanisms 
Inflammatory biomarkers were independently associated with HRV even after 
comprehensive adjustment for lifestyle factors and other cardiovascular health metrics. This 
multivariable adjustment is very important, given the known relationships of lifestyle factors 
and cardiovascular health metrics with inflammation and HRV. Consistent with other studies, 
we could show an inverse association between SDNN and hs-CRP.71,74,75 Our studies 
expand these prior studies by showing inverse associations with other inflammatory markers 
such as LC, neutrophils, lymphocytes and monocytes. Hs-CRP and LC are representing 
different inflammatory pathways. Therefore we hypothesize that different inflammatory 
pathways are involved in the relationship with the ANS.  
Experimental studies have shown the expression of adrenoceptors on immune cells, 
assuming a direct influence of adrenoceptor agonists on the immune system.95,96 As a 
consequence of sympathectomy, other studies could demonstrate reduced inflammatory 
reactions.97 Moreover, vagal activity seems to have an anti-inflammatory effect, resulting in a 
down-regulation of pro-inflammatory cytokines.91 In addition, immune cells may directly 
influence the ANS via the cytokine interleukin-1.92  
Normalized HF, mainly modulated by parasympathetic activity, showed negative associations 
with neutrophils and monocytes. These inverse relationships may show an anti-inflammatory 
effect of vagal modulation or increased vagal modulation based on low immune cell count. In 
contrast, a positive association was found between normalized HF and lymphocytes. A 
previously published study among over 3300 patients scheduled for coronary angiography, 
could show an adverse effect for neutrophils and a protective effect of lymphocytes regarding 
the risk for cardiovascular events.98,99 The strong association of hs-CRP with normalized LF 
and SDNN, but not with normalized HF is supported by another small study among middle-
aged men,74 suggesting an association with mainly sympathetic modulation of HR. Based on 
our data, it is not possible to fully explain the accurate underpinnings of these findings, which 
highlights the importance to perform further basic and clinical research to completely 
understand the interrelationship of individual inflammatory biomarkers and the ANS.  
 
8.1.3 Heart rate variability, heart rate and its relationship 
Similar to HRV, resting and ambulatory HR are associated with an increased risk of 
cardiovascular events in general populations.76,77 Moreover, HR has shown to be an 
important predictor of mortality in diseased populations.100,101 Among our young population, 
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resting and ambulatory HR were strong linearly associated with the lifestyle-score, sleep-
related breathing disorders and inflammatory biomarkers.  
As the term HRV already implies, HRV is based on two quantities: the HR and its variability. 
A certain dependence of both entities is therefore assumable. However, it is highly discussed 
to what extent HRV is depending on HR and whether HR is playing the principal role in the 
prognostic value of HRV. About 20 years ago, Tsuji et al. showed a tight inverse relationship 
between HR and time- and frequency domain HRV.81 This strong association was resumed 
in recently published studies, explaining the physiological and mathematical interaction of the 
relationship between HR and HRV.55,102 Monfredi et al. conducted an experimental study 
using different cardiac cells of healthy and diseased humans and animals.55 Plotting HR and 
time-domain HRV of these preparations, they could graphically show an inverse, non-linear 
relationship (Figure 4, page 8). The authors conclude to always consider changes of HR 
when investigating relationships with HRV.55 Tsuij et al. could show similar relationships not 
only with time- but also with frequency-domain variables (HF and LF).81 Simultaneously, they 
found that this relationship markedly differs across age decades with a strong relationship in 
young individuals and a weak inverse relationship among older individuals.81 In other words, 
the dependence of HRV (mainly LF and HF) and HR is weaker in the elderly compared to the 
young.81 This finding could be explained by the impaired autonomic modulation of the sinus 
node in the elderly. The age-dependent relationship between HR and HRV could be one 
reason for the strong attenuation of our relationships when adjusting for HR. Sacha et al. 
demonstrated that the prognostic value of HRV regarding cardiovascular outcomes is mainly 
based on HR.102,103 However this assumption is based on complex mathematical models. 
The mentioned studies highlight the complexity of the relationship between HRV and HR. It is 
necessary to further investigate the additional benefit and the prognostic value of HR and 
HRV, independent of each other.  
On the basis of the above mentioned studies, we have decided to additionally adjust all our 
analyses for resting and ambulatory HR. All relationships were strongly attenuated by the 
additional adjustment for HR. The attenuation of these results was stronger for 24-h HR 
compared to resting HR, in order that only few relationships remained significant. In contrast, 
adjusting the relationships between HR and lifestyle, inflammatory biomarkers or sleep-
related breathing disorders with HRV, most relationships were attenuated but remained 
significant. We therefore suggest that HRV and mainly 24-h HR carry a high amount of 
common information. Whether HR is on the path of the relationship between the variables of 
interest and HRV remains unclear. 
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8.1.4 Prevalence of a healthy lifestyle and sleep-related breathing disorders 
Adopting a healthy lifestyle is highly promoted by different institutions to reduce risk factors 
for morbidity and mortality. To estimate the current prevalence of people adopting a healthy 
lifestyle is of high interest. To be able to intervene and to launch new prevention programs, 
the current situation has to be known and analyzed. Among our young western European 
study population, only a minority of the population, namely 11%, has adopted a 
comprehensive healthy lifestyle (score of 6 or 7), which is based on the recommendations of 
the American Heart Association (AHA). Women had a higher lifestyle-score compared to 
men. Our results are in line with other studies among US populations, using the identical 
score to estimate lifestyle. According to data of the ARIC study, only 3% of the study 
population adopted a healthy lifestyle. Women and Caucasians were more likely to adopt a 
healthy lifestyle compared to men and African Americans.8 Another US study, using data of 
the National Health and Nutrition Examination Survey (NHANES), showed an increasing 
prevalence of individuals with an unhealthy lifestyle over the last 20 years.9 Consumption of a 
healthy diet had a very low prevalence in our study population. This result is supported by 
another study, where they also showed a low prevalence of people consuming a healthy 
diet.9,104 In our cohort, the prevalence of men having an ideal BP was impressively low with 
18% compared to 66% among women. Thinking about the high influence of high-normal BP 
and manifest hypertension on the risk for cardiovascular events,105,106 it is crucial to intervene 
and to educate and sensitize the population.  
As elucidated in the background, there is a close link between the occurrence of sleep-
related breathing disorders, lifestyle factors and cardiovascular risk factors, especially BMI. 
According to data of the Wisconsin Sleep Cohort Study, the prevalence of sleep-related 
breathing disorders has markedly increased over the last 20 years among men and 
women.107 This increase parallels the increasing prevalence of obesity.9 Overall, 9.6% of our 
study participants had sleep-related breathing disorders, of whom 83% were male. The 
Epworth Sleepiness Scale, as an indicator for daytime sleepiness, was similar among 
participants with an AHI≥5 or an AHI<5, assuming that affected participants may be at an 
early, asymptomatic stage of the disorder. Based on data of the population-based 
CoLaus/PsyCoLaus study, Heinzer et al. found a prevalence of mild sleep-related breathing 
disorders (AHI≥5) of 83.8 and 60.8% among men and women, respectively.15 In contrast to 
our study, the median age of the population was 57 years, individuals had more co-
morbidities and the diagnosis was obtained by polysomnography. In accordance with other 
studies, we could show a distinct difference in the prevalence of sleep-related breathing 
disorders among both sexes. In the population investigated by Heinzer et al., this difference 
seems to diminish with the age of 60 years, assuming an influence of the hormonal status in 
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women.15 This finding is supported by another study, showing that the prevalence of sleep-
related breathing disorders among postmenopausal women with hormone replacement 
therapy was markedly lower compared to women without replacement therapy.108 Due to the 
collapsing airways and the interruption of ventilation in patients with OSA, hypertension often 
co-exists.16,18 We also made this observation in our young and relatively healthy population 
with subclinical and early forms of sleep-related breathing disorders. Based on the tight link 
between sleep-related breathing disorders, lifestyle and cardiovascular risk factors, it is very 
likely to lower the prevalence of both obesity and sleep-related breathing disorders when 
adopting a healthy lifestyle. Our results therefore implicate that promoting a healthy lifestyle 
should remain a key issue on the agenda of professional societies and governments.  
As an example of a prevention program, the American Heart Association formulated public 
health goals, which target cardiovascular health metrics and lifestyle factors. The American 
Heart Association’s 2020 impact goals have the aim to improve cardiovascular health by 
20% and reduce deaths from CVD and stroke by 20% while targeting seven lifestyle factors 
and cardiovascular health metrics, which are known as Life’s simple 7 behaviors.109 Such 
nation-wide prevention programs, but also a lot of smaller interventions programs will be 
necessary in order to reduce cardiovascular risk and adverse cardiovascular outcomes in the 
general population.  
 
8.2 Methodological aspects – Strengths, limitations and challenges  
Conducting observational research is challenging and needs a lot of financial, technical and 
personal resources. Study investigators have to perform a balancing act between the 
feasibility of a study and the requirements and own ideas to investigate a certain research 
question. The feasibility of a study is of high importance and does often co-determine the 
choice of measurement instruments.110 Repeatedly, important decisions have to be made to 
find a compromise between the ideal assessment of an item and the practicability of the 
measurement in the planned context. In case of the GAPP-study we have tried to assess 
items best possible without ignoring the feasibility and the time expenditure for the study 
participants. As the GAPP-study is a prospective study, it is of high important that 
participants remain motivated to participate in the study. In general, it is also crucial to use 
validated measurement instruments to be sure that the instrument measures what it is 
supposed to measure. All measurement procedures in our study were highly standardized 
using written standard operating procedures (SOP) to minimize the risk of systematic errors. 
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Moreover, all employees of the GAPP-study are familiar with Good Clinical Practice (GCP) 
and are working according the GCP guidelines.  
Even though we gave our best to perform reliable research, several aspects have to be 
discussed regarding the methods of the study and the interpretation of our study results. In 
the following paragraphs, the assessment of main study variables will be discussed, as well 
as the main study limitations, the relevance of the study and finally further implications for 
research. 
 
8.2.1 Measurement instruments and assessment of study variables 
Assessment of heart rate variability  
In this study, HRV was assessed over 24 hours, while participants performed their daily 
activities. Compared to short-term HRV recordings, the long-term HRV assessment is 
commonly known as the gold-standard. However there are plenty of studies, where HRV is 
assessed using short-term ECG recordings of 2, 5, 10 minutes or even 2 hours. A common 
convention about the duration of short-term recordings does not exist. However, at least 2 
minutes of recording are necessary to assess the HF and LF components of HRV.43 Since 
total variance of HRV is changing with the duration of ECG recording, the absence of a 
standardized short-term recording duration might be a disadvantage. To compare absolute 
HRV values across different individuals is therefore difficult.43 Based on the change in total 
variance, the distribution of frequency-domain variables is markedly different in short-term 
recordings compared to long-term HRV recordings. In any case, one should be careful when 
comparing results of HRV analysis with different ECG recording durations and should be 
aware of this problem. However, independent of the recording length, short-and long-term 
HRV has shown to be associated with cardiovascular risk and events.47,48,58 
Another important point to consider is to use of a well-functioning software to edit ECG 
recordings. Artefacts may have a crucial influence on HRV values, which makes the editing 
process enormously important. This process includes the removal of artefacts but also the 
redefinition of premature ventricular and atrial beats. The quality of the Holter ECG 
recordings in our study was very high, which resulted in an editing time of 10.2 minutes per 
Holter-ECG. Two researchers were trained by a cardiologist to perform the editing process. 
Trainings were regularly repeated in order to maintain high quality standards. Difficult cases 
were discussed together with an experienced electrophysiologist.  
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Due to feasibility reasons, study participants carried the 24-h ECG device simultaneously 
with a 24-h BP monitoring device. To wear both devices simultaneously could be impairing 
for some participants. Therefore, it is possible that the behavior of some individuals was 
different compared to normal days. Unfortunately, there are no possibilities of controlling for 
this behavior. Nevertheless, we are confident that this phenomenon is attenuated with 
increasing sample size.  
The task force of the European Society of Cardiology and the North American Society of 
Pacing and Electrophysiology recommend a recording duration of at least 18 hours for long-
term ECG recordings.43 In our study we have defined a cut-off of at least 80% of the maximal 
duration of 24 hours, which results in a cut-off of 19.2 hours. Participants with recording 
durations below this cut-off were asked and motivated to repeat the recording. Even though 
overall quality of the ECG recordings was very high, we had to exclude ECG recordings of 22 
participants. Moreover, 20 participants have denied to perform a 24-h ECG or had technical 
device issue during 24-h ECG recording.  
 
Assessment of physical activity and other lifestyle factors 
Lifestyle factors, such as physical activity, diet and smoking status were self-assessed using 
standardized questionnaires. Questionnaires are commonly used in epidemiological studies 
with a large sample size and are a helpful tool to assess different items. Using 
questionnaires has several advantages and disadvantages, which should be taken into 
account before deciding for or against their use. Important advantages are the low costs, the 
easy way of distribution as well as the potential of saving time. Moreover, the questionnaires 
used in the GAPP-study were scanned and data were automatically entered in the dataset. 
One main disadvantage of using questionnaires is that the assessment is subjective and 
there remain a potential uncertainty. Recall and response bias, which also includes social 
desirability bias, may occur and are difficult to control.111,112 Social desirability bias is based 
on the phenomenon that some individuals tend to answer what they think is more esteemed 
in the society. As an example, individuals might overestimate their physical activity because 
they know that being physically active is healthy. Even though these sources of uncertainty 
when using questionnaires, we expected that these potential biases can be minimized when 
increasing the number of study participants. 
Diet was assessed using the official questionnaire of the Federal Office of Public Health 
(Swiss health survey 2007), where information about the frequency of fruit, vegetable, meat, 
fish or dairy consumption was assessed. While diet and smoking status are often ascertain 
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using questionnaires there are several options to assess physical activity.113 The choice of 
one specific method to assess physical activity is depending on the research question and 
the resources and possibilities of the study. The short IPAQ is an international and commonly 
used questionnaire assessing habitual moderate and vigorous physical activity and time 
spent for walking and sedentary activities. The validity and reliability of the short IPAQ was 
evaluated in an international population aged 18 to 65 years and achieved acceptable 
measurement properties.83 As always with questionnaires, one should be aware that 
collected data remain an approximation of the true result. The IPAQ is assessing information 
about the frequency and duration of physical activity, which could be misjudged by study 
participants. Moreover, seasonal changes might play an important role and could be included 
in the estimation of the participants.114 Underreporting may occur if individuals do not remark 
physical activity (mainly moderate physical activity) in their daily routine. In contrast, 
individuals may include socializing, theoretical instructions or refreshments in the physical 
activity duration.  
 
Lifestyle and cardiovascular health metrics score 
Adopting a healthy lifestyle is highly promoted by professional societies and governments.6,7 
To investigate associations of a healthy lifestyle as a whole construct with different outcomes 
is therefore essential. As a consequence, different scores, based on lifestyle factors and/or 
cardiovascular health metrics, were constructed. Up to now, there is no consensus for the 
use of one specific score. 
For our project, we have chosen a score, which is based on the American Heart Association 
(AHA) definition of ideal cardiovascular health metrics. As reported in the manuscript in 
chapter 4, this score consists of a broad set of cardiovascular health metrics and lifestyle 
factors, such as smoking, physical activity, diet, BMI, blood pressure, total cholesterol and 
HbA1c levels. Until now, this score was used in different US cohort studies with middle-aged 
adults from the general population, where they showed a strong association with 
cardiovascular outcomes and mortality.8,9 However, there remain several issues concerning 
the score that should be discussed in the following section.  
BMI is a widely used variable to assess body weight in relation to height with a universal 
classification independent of sex. The most important disadvantage of the BMI is that body 
composition is not taken into account. Based on the higher average muscle mass of men 
compared to women, BMI in men is often overestimated. Using the BMI as a risk predictor is 
therefore not always reliable. Sex-specific calculations or cut-offs might be one solution. 
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WHR for example, an easily measurable marker, takes into account the distribution of body 
fat. Universal and sex-specific cut-offs for WHR exists. Several studies showed that WHR is 
a stronger predictor for future cardiovascular events compared to BMI.115-117 Therefore, 
including WHR instead of BMI into the score should be considered as a meaningful 
alternative.  
Total cholesterol is one of seven components of the lifestyle-score. Taking into account the 
strong association of LDL with cardiovascular outcomes,118 the inclusion of LDL instead of 
total cholesterol could be a good option. For a sensitivity analysis, we have modified this 
score accordingly, using a LDL cut-off of 160 mg/dl. As presented in chapter 4, this 
modification had no consequences on the relationship between HRV and the lifestyle-score.  
High BP is one of the most important cardiovascular risk factors. To include this strong risk 
factor in the score is therefore justified. However, it could be discussed whether conventional 
BP levels, measured in the doctor’s office, or ambulatory 24-h BP levels are more useful and 
reliable. Ambulatory 24-h BP levels have shown to be a stronger predictor for cardiovascular 
outcomes compared to conventional BP.119,120 Another study showed a high proportion of 
young individuals with a masked hypertension (27% among men), meaning that they have 
normal conventional BP, but an elevated ambulatory BP.121 With regard of our young study 
population, a remarkable proportion of our study participants could be misclassified. 
Nevertheless, compared to conventional BP measurement, ambulatory 24-h BP monitoring 
needs markedly more time and financial resources and it seems therefore not realistic to 
commonly include 24-h ambulatory BP levels into the score.  
In the original AHA based score, diet relies on five dietary items, including salt consumption, 
fish intake, fruit- and vegetable intake, consumption of sweet beverages and whole grain 
consumption. The questionnaire we used for our study does not assess information about 
the consumption of sweet beverages and whole grains. This forced us to modify the 
definition of an ideal diet. We are aware of this problem and cannot rule out that this 
modification might have an influence on our study results.  
 
Assessment of sleep-related breathing disorders 
Polysomnography is the current standard diagnostic tool for the diagnosis of sleep-related 
breathing disorders. This procedure is rather complex and expensive and is done stationary 
in a sleep laboratory. Polysomnography is a multichannel recording of electromyographic, 
electroencephalographic and respiratory activity together with an ECG to detect any 
breathing disorders during sleep.16 Because of the financial resources, the sample size and 
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feasibility of the study, we have decided to instead perform a nighttime pulse oximetry 
including nasal airflow measurement, which can be handled by the study participants 
independently.  
This portable device (ApneaLink, Resmed, USA) was validated in a validation study and data 
were compared to simultaneously recorded polysomnographic data.122 AHI and ODI 
assessed using the ApneaLink device were compared to the AHI based on the 
polysomnography. The sensitivity for AHI was ≥ 90% with a very high specificity. The ODI 
had a good overall sensitivity (≥80%). However, there was a lower specificity, especially at 
lower polysomnographic AHI levels. This may lead to a higher number of false positive 
results.122 In our analysis (chapter 5), 120 individuals had an AHI≥5 while 141 participants 
had an ODI ≥5. This difference might partly be reasoned by the lower specificity of the ODI. 
Despite we have not used the gold-standard method for the assessment of sleep-related 
breathing disorders, we are confident that the usage of the ApneaLink device including pulse 
oximetry and nasal airflow was the best possible solution to investigate our study research 
questions.  
Nocturnal pulse oximetry and nasal air flow measurement was routinely implemented about 
one year after the official start of the baseline examination. Therefore, 610 participants were 
included in the study before having initiated this measurement. In addition, 127 participants 
have declined to perform this analysis or had artificial fingernails, which did not allow the 
nocturnal pulse oximetry. Unfortunately, among several participants the recording duration of 
either nocturnal pulse oximetry or nasal airflow measurement was too low, leading to the 
exclusion of these recordings (n=114). One reason for a shorter recording duration was a 
shift of the nasal cannula in order that nasal airflow could not be measured. To avoid this 
problem, we have instructed participants to fix the nasal cannula with tape on both cheeks. A 
few participants reported that they could only breathe through the mouth, which of course 
resulted in no recording time of the air flow measurement. Other participants reported of 
having lost the pulse oximetry device during night. Overall, the device was well tolerated of 
the participants and easy to handle.  
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8.2.2 Study limitations – Consequences for the interpretation of the results 
The GAPP-study is a population-based cohort study in the Principality of Liechtenstein, 
which was designed to investigate the development of cardiovascular risk factors in an 
initially young and healthy population. The study population is large and well-characterized 
and we are not aware of another study with similar population characteristics. Based on our 
inclusion and exclusion criteria, we are confident that our study sample is representing a 
western European population in a given age range. Despite various strengths, several 
limitations have to be taken into account when interpreting the study results in order to avoid 
wrong conclusions and misunderstandings. 
Based on the nature of cross-sectional data it is not possible to draw any causal 
assumptions. Prospective, longitudinal data are needed to make statements about the 
directionality of relationships. This is a very important issue to consider in order to avoid 
misunderstandings when interpreting the results. Causality is a complex term and different 
definitions exists.123 In brief, causality means that an exposure is fully or partly causing a 
certain outcome. Causality is based on several criteria. Bradford Hill has established ‘Hill’s 
criteria for causation’, which are consisting of strength (effect size), specificity, plausibility, 
consistency, biological gradient, temporality, coherence, experiment and analogy. These 
criteria should be met to have enough evidence for causality.124 Thus, lot of research is 
needed to detect causal relationships. 
When interpreting the study results, it is important to consider that the generalizability of our 
results is not certain. Even though we are confident that the GAPP study population is 
representing a general western European population in the given age range, it is uncertain if 
similar results could be expected in other populations. Generally, the generalizability of study 
results depends on several aspects, such as internal and external validity, the 
representativeness of the sample, potential bias and the statistical power.125  
Study errors may happen. It is crucial to minimize the occurrence of random errors and to 
avoid systematic errors as efficiently as possible. The research process consists of different 
steps126 where both types of errors may originate. To reduce the risk of errors, the individual 
research steps, such as selecting a sample, collecting or processing data, should be 
thoroughly studied when planning the study.126 Since random and systematic errors have 
different consequences regarding the results, the discrepancies are further elucidated in this 
paragraph. Random errors are also known as ‘noise’ and have no directionality. Therefore it 
is expected that random errors will not have an effect on the results, especially with 
increasing sample size. In contrast, systematic errors or so called bias might have a high 
impact on the results and have to be avoided as best as possible.127 There exist no valid 
8.DISCUSSION 
 
107 
 
methods to correct for systematic errors. Bias may occur at different levels of the study, e.g. 
due to a poor recruitment strategy, unfavorable measurement procedures, uncalibrated 
devices, deficient data entry or data analysis. Selection bias is one of the most important 
biases that may occur in cohort and randomized studies. Based on our recruitment strategy 
and given circumstances in the Principality of Liechtenstein we are confident that we could 
minimize the risk of selection bias. First, we had the opportunity to invite all inhabitants of the 
Principality of Liechtenstein in the given age range due to a collaboration with local 
authorities. Second, since Liechtenstein is a rather small country and the study center is well 
located, it is assumable that all inhabitants are able to reach the study center in less than 20 
minutes by car. Third, inhabitants of the Principality of Liechtenstein get a biannual health 
check by their general practitioner, which is paid by the government. Therefore, we expect no 
selection of individuals with less financial resources, who might have a high interest of 
getting a health check for free. In contrast, there was a certain selection regarding the age. It 
has to be noted that markedly more individuals around 40 years were participating in the 
study than younger individuals around 25 years. This might be explained by a higher health 
interest of older participants. A further potential bias might be the information bias, including 
observer and recall bias. Applying standardized procedures, we tried to minimize the risk of 
an observer bias. Moreover, it is an advantage to have an experienced study team in our 
study center.  
As in any observational study, confounding is one of the most important problems and may 
lead to false associations. By definition, a confounder has an association with the 
independent and dependent variable but is not on the casual pathway of the relationship of 
interest.128 Potential confounders have to be taken into account and need to be included into 
statistical models to adjust for them. The GAPP study population is well-characterized, which 
allows the adjustment for many various potential confounders. However, to be able to adjust 
for a certain confounder, researchers have to be aware of these possible confounders. Of 
course these variables also need to be assessed and available for calculations. Therefore, 
despite a well-performed characterization, residual confounding is nearly unavoidable. To 
minimize the risk and influence of residual confounding, investigators have to think about 
potential confounders when planning and setting up a study and of course before starting a 
statistical analysis. 
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8.2.3 Relevance, implication and perspective 
Relevance and implications of the study 
In our study population, the prevalence of a healthy lifestyle was relatively low, especially 
among men. These findings highlight the importance that promoting a healthy lifestyle in the 
general population should remain a key priority of governments and public health 
associations. Based on our data, public health associations may detect and analyze certain 
problems, which allow them to develop specific public health interventions. Educational 
programs, including presentations or workshops, could help to further educate the population 
regarding their lifestyle, the most important cardiovascular risk factors and the resulting 
consequences. It can be assumed that individuals of a western European population are well 
educated and are theoretically aware of the adverse consequences of an unhealthy lifestyle 
and cardiovascular risk factors. However, to increase the awareness regarding unhealthy 
habits and the willingness to modify habitual behaviors of young adults should further be 
promoted. On the other hand, the personal environment of every individual should be formed 
in order to keep the needed effort to be physically active or to consume a healthy diet as low 
as possible. Employers or health insurances may have great potential to increase the 
motivation or willingness of individuals to adopt a healthy lifestyle. Employers and insurances 
should both be interested in keeping their employees or clients as healthy as possible, which 
clearly results in a win-win situation for both sites.  
The investigated relationships showed a strong link between the autonomic function and the 
investigated entities. This is even more impressive when thinking about the young and 
relatively healthy study population and shows that these links are an early and linear 
phenomenon. Early abnormalities in the function of the ANS might partly be responsible for 
the occurrence of cardiovascular events later on and are therefore important to further 
investigate. This current project was necessary to further develop new research questions 
and to analyze the association in a longitudinal setting in order to assess the directionality.  
 
Outlook and recommendations for future studies 
New research is based on current evidence and existing gaps in knowledge. Based on the 
results of our study, several new research questions can be develop with the aim to better 
understand the influence of possible predictors on changes in HRV over time, the meaning of 
the HRV and its relationship with HR, and finally to elaborate the potential role in clinical 
routine.  
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The current project is based on cross-sectional analyses and no assumptions about the 
direction of the association are allowed. However, since the GAPP-study is a prospective 
cohort study and the first follow-up is currently ongoing with 800 participants completed, it is 
foreseeable to perform longitudinal analysis to be able to investigate associations of the ANS 
and assessed variables in a longitudinal setting. First of all, it would be of great interest to 
observe the progression of individual HRV parameters and to investigate potential predictors 
for the change in HRV values over time. Longitudinal population based studies of an initially 
healthy population are rare and could therefore shed new light on HRV and the mechanisms 
of the ANS. Independent of HRV, observing the change in prevalence of the lifestyle-score 
and sleep-related breathing disorders over the years could be of high interest not only from a 
scientific point of view, but also from a public health point of view.  
24-h HRV was associated with sleep-related breathing disorders. To check, whether this 
there is the same association during day- and nighttime would be interesting. Therefore, 
separate day- and nighttime analyses are desirable and should be performed in the future. 
Moreover, we have the opportunity to prospectively analyze this association. Population-
based studies in this area are very rare, so that we could highly contribute to improve 
knowledge in this area.  
Two new measurement instruments were integrated into our study procedure 1) to measure 
physical activity over several days using an activity tracker and 2) to estimate psychological 
well-being using a validated questionnaire. Participants are wearing the activity tracker on 
their non-dominant wrist in form of a bracelet, which is mainly counting the steps performed. 
Using this device, we hope to better evaluate physical activity as we have now the reported 
habitual physical activity as well as the measured activity. First of all, it would be interesting 
to compare reported activity versus measured activity. In a second step the role of measured 
physical activity on the change of HRV should be investigated. Besides, to investigate 
psychological well-being as a potential predictor of the change in HRV would be interesting, 
in order to check the influence of the psychological status on physiological processes.  
With the recent publication of Monfredi et al.,55 where they showed a strong inverse 
relationship between HR and HRV, this topic became of high interest, even though Tsuij et 
al.81 described similar associations 20 years ago. Considering their thoughts as well as our 
study results, HR and HRV seem to have a lot of common information. In contrast to HR, 
individual HRV variables have a physiological correlation and are therefore directly linked to 
the ANS.43 However, it is important to point out that mainly the HF component of the HRV 
could be experimentally assigned to parasympathetic modulation.129 The evidence for the 
physiological correlation of other HRV variables is rather poor. Thus, the question rises why 
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all these HRV variables are absolutely needed. In order to take this question up, it is 
necessary and would be of high interest to better evaluate the benefit and the additional 
information of HRV variables over HR. Mainly the complex frequency domain variables have 
some potential and should further be researched. Since there exists several HRV variables, it 
would additionally be relevant to investigate whether all HRV variables are necessary or if 
some variables have the same content or meaning.  
Further studies are needed to investigate the utility of the HRV in the clinical routine. HRV 
values are depending on various physiological factors as well as the recording time. 
Comparisons of absolute HRV levels between individuals are therefore difficult, even though 
some reference levels exist.130 However, HRV might have prognostic impact when observing 
it over time in the same patient. The observation of the progression of HRV might allow 
statements about the course of the patient’s health. To clarify this assumption and the 
potential in the clinic, clinical studies should be planned to assess the relationship between 
the relative change in HRV and clinical outcomes. Moreover short-term HRV might become 
an important screening tool for paroxysmal atrial fibrillation, which could help to decide 
whether further accurate evaluation is needed. Though, it is essential to point out that a lot of 
research and resources are needed to integrate HRV one day into clinical routine.  
Finally, basic research should be supported, in order to better understand the influence of 
autonomic dysbalances on the development of CVD. Moreover, the development of new 
therapeutic approaches that directly intervene and modify the ANS in direction of a more 
balanced system are needed and may probably prevent future cardiovascular events.  
 
8.3 Conclusion 
In order to evaluate the multifaceted association between lifestyle and lifestyle-related factors 
with the autonomic function, we have assessed the relationship of HRV with a healthy 
lifestyle, sleep-related breathing disorders and inflammatory biomarkers in a young and 
relatively healthy population. Based on the strong associations with HRV, we suggest 
interrelationships between the ANS and these entities. Not only HRV, but also resting and 
24-h HR was strongly associated with these independent factors. Adjusting the associations 
of HRV and lifestyle, sleep-related breathing disorders and inflammatory biomarkers with HR, 
most relationships lost level of significance. Therefore it is assumable that most of the 
information of HRV seems to be contained in mainly 24-h HR and the incremental 
information of HRV parameters was modest. Even though the directionality of our association 
cannot be proven, these data may allow some insights in the pathophysiology of CVD 
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occurrence. Additionally, the adoption of a healthy lifestyle was rather low in this young 
population, which underscores the importance of healthy lifestyle promotion in the society. 
Based on this research project new research questions can be developed to further 
understand the role of the ANS in the relationship between lifestyle and lifestyle-related 
factors and the increased risk for cardiovascular events.  
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